Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.50 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.48 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.48 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29429847 | 1.00 | ENPP2 (0.50) | ENPP2ORAI1ORAI2ORAI3NFE2L2 | |
| SCHEMBL30868908 | 0.87 | ENPP2 (0.37) | ENPP2ORAI1ORAI2ORAI3NFE2L2 | |
| SCHEMBL203282 | 0.85 | ENPP2 (0.60) | ENPP2ORAI1ORAI2ORAI3HPGD | |
| SCHEMBL25960385 | 0.85 | ORAI1 (0.46) | ENPP2ORAI1ORAI2ORAI3NFE2L2 | |
| SCHEMBL32680120 | 0.83 | ENPP2 (0.46) | ENPP2ORAI1ORAI2ORAI3NFE2L2 | |
| SCHEMBL22972697 | 0.82 | NFE2L2 (0.44) | ENPP2ORAI1ORAI2ORAI3NFE2L2 | |
| SCHEMBL28580785 | 0.80 | PTPN1 (0.41) | ENPP2ORAI1ORAI2ORAI3NFE2L2 | |
| SCHEMBL12538688 | 0.79 | CA1 (0.41) | HPGDALDH1A1LMNAKMT2ACA1 | |
| SCHEMBL29954395 | 0.79 | CA1 (0.41) | HPGDALDH1A1LMNAKMT2ACA1 | |
| SCHEMBL954824 | 0.79 | L3MBTL1 (0.50) | ALDH1A1MAPTMAPK1L3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 952 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4058453-B1 | IMPROVED SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC (US) | 2025-12-24 | — | — | EP | claimed |
| US-12466825-B2 | Synthesis of KRAS G12C inhibitor compound | AMGEN INC. (US) | 2025-11-11 | — | — | US | claimed |
| US-20250194617-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2025-06-19 | — | — | US | claimed |
| US-20250179068-A1 | SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. (US) | 2025-06-05 | — | — | US | claimed |
| US-20250169514-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2025-05-29 | — | — | US | claimed |
| CN-114728960-B | Improved synthesis of KRAS G12C inhibitor compounds | 美国安进公司 | 2025-05-27 | — | — | CN | claimed |
| US-20240254150-A1 | CONFORMATIONALLY RESTRICTED SULFONATE BASED PHOSPHINE LIGANDS FOR HINDERED SUZUKI COUPLING REACTIONS | TCG GreenChem Inc. (US) | 2024-08-01 | — | — | US | claimed |
| US-20230380457-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2023-11-30 | — | — | US | claimed |
| EP-4280882-A2 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. (US) | 2023-11-29 | — | — | EP | claimed |
| US-20230363426-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2023-11-16 | — | — | US | claimed |
| US-11793220-B2 | Materials and methods for extending shelf-life of foods | JP LABORATORIES, INC. (US) | 2023-10-24 | — | — | US | claimed |
| CN-116916755-A | Materials and methods for extending the shelf life of food products | JP实验室公司 | 2023-10-20 | — | — | CN | claimed |
| US-20220264914-A1 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. | 2022-08-25 | — | — | US | claimed |
| US-20220225647-A1 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. | 2022-07-21 | — | — | US | claimed |
| US-20220225646-A1 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. | 2022-07-21 | — | — | US | claimed |
| US-8361484-B2 | Polymer systems for lung volume reduction therapy | AERIS THERAPEUTICS, INC. (US) | 2013-01-29 | — | — | US | claimed |
| US-20100040538-A1 | Polymer Systems for Lung Volume Reduction Therapy | CANADIAN IMPERIAL BANK OF COMMERCE (CA) | 2010-02-18 | — | — | US | claimed |
| EP-2059227-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | Aeris Therapeutics, Inc. (US) | 2009-05-20 | — | — | EP | claimed |
| WO-2008039827-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | AERIS THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | claimed |
| US-12630547-B2 | RAS protein degraders, pharmaceutical compositions thereof, and their therapeutic applications | BIOTHERYX, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| CN-116829557-B | Pentaheterocycle compound, preparation method and application thereof | 上海艾力斯医药科技股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20260115297-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1 | ICAHN SCHOOL MED MOUNT SINAI (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4234546-B1 | IMPROVED SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12582657-B2 | Combination therapy including a KRAS G12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | AMGEN INC. (US) | 2026-03-24 | — | — | US | disclosed |
| EP-3773573-B1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC INC (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMA INC (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4703359-A1 | IMIDAZOPYRIDINE OR IMIDAZOPYRAZINE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2026-03-04 | — | — | EP | disclosed |
| US-20260049074-A1 | THIADIAZOLYL DERIVATIVES | IDEAYA BIOSCIENCES, INC. (US) | 2026-02-19 | — | — | US | disclosed |
| US-12552804-B2 | Tricyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2026-02-17 | — | — | US | disclosed |
| US-12552783-B2 | Modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4685160-A2 | COMBINATION THERAPY INCLUDING A KRASG12C INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS | Amgen Inc. (US) | 2026-01-28 | — | — | EP | disclosed |
| US-12516059-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2026-01-06 | — | — | US | disclosed |
| US-12509454-B2 | Thiadiazolyl derivatives | IDEAYA BIOSCIENCES, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250388579-A1 | SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. (US) | 2025-12-25 | — | — | US | disclosed |
| EP-3883579-B1 | COMBINATION THERAPY INCLUDING A KRAS-G12C INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS | AMGEN INC (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-4058453-B1 | IMPROVED SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12503445-B2 | Compounds and their use | ASTRAZENECA AB (SE) | 2025-12-23 | — | — | US | disclosed |
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-12497396-B2 | Nitrogen-containing heterocyclic derivatives, method therefor and application therefor as inhibitors of KRAS G12C for the treatment of cancers | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2025-12-16 | — | — | US | disclosed |
| US-20250368642-A1 | SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250368643-A1 | SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250362134-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2025-11-27 | — | — | US | disclosed |
| US-20250346585-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2025-11-13 | — | — | US | disclosed |
| US-12466825-B2 | Synthesis of KRAS G12C inhibitor compound | AMGEN INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-12466815-B2 | Carboxamide compounds and uses thereof | INCYTE CORPORATION (US) | 2025-11-11 | — | — | US | disclosed |
| US-12465648-B2 | Heterobifunctional compounds as degraders of HPK1 | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2025-11-11 | — | — | US | disclosed |
| US-12459940-B2 | Oxazole compound as multi-targeted inhibitor of IRAK4 and BTK | Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. (CN) | 2025-11-04 | — | — | US | disclosed |
| WO-2025224168-A1 | ARYL SULFONE AND SULFANONE DERIVATIVES AS OREXIN RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-10-30 | — | — | WO | disclosed |
| US-20250325552-A1 | SUBSTITUTED THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4634170-A1 | IMIDAZO[4,5-B]PYRIDINE DERIVATIVES AS PCSK9 INHIBITORS AND METHODS OF USE THEREOF | AstraZeneca AB (SE) | 2025-10-22 | — | — | EP | disclosed |
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-12441727-B2 | Tricyclic compounds as inhibitors of KRAS | INCYTE CORPORATION (US) | 2025-10-14 | — | — | US | disclosed |
| EP-4628490-A2 | NLRP3 INFLAMMASOME INHIBITORS | Astrazeneca AB (SE) | 2025-10-08 | — | — | EP | disclosed |
| EP-4363406-B1 | NLRP3 INFLAMMASOME INHIBITORS | ASTRAZENECA AB (SE) | 2025-09-10 | — | — | EP | disclosed |
| US-12410187-B2 | Fused tricyclic compounds useful as anticancer agents | ASTRAZENECA AB (SE) | 2025-09-09 | — | — | US | disclosed |
| US-12402638-B2 | Materials and methods for extending shelf-life of foods | JP LABORATORIES, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| EP-4602041-A1 | HPK1 INHIBITORS AND METHODS OF USE THEREOF | Arcus Biosciences, Inc. (US) | 2025-08-20 | — | — | EP | disclosed |
| EP-3998264-B1 | OXAZOLE COMPOUND AS MULTI-TARGETED INHIBITOR OF IRAK4 AND BTK | SHANGHAI FOSUN PHARMACEUTICAL IND DEVELOPMENT CO LTD (CN) | 2025-08-20 | — | — | EP | disclosed |
| US-12391691-B2 | Synthesis of key intermediate of KRAS G12C inhibitor compound | AMGEN INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-12391689-B2 | Synthesis of key intermediate of KRAS G12C inhibitor compound | AMGEN INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-12384778-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250236621-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2025-07-24 | — | — | US | disclosed |
| EP-3351533-B1 | BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME | KAKEN PHARMA CO LTD (JP) | 2025-07-23 | — | — | EP | disclosed |
| US-RE50490-E1 | Substituted quinazoline compounds and methods of use thereof | ARAXES PHARMA LLC (US) | 2025-07-15 | — | — | US | disclosed |
| US-20250206735-A1 | SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. (US) | 2025-06-26 | — | — | US | disclosed |
| US-20250197381-A1 | SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-19 | — | — | US | disclosed |
| US-20250194617-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2025-06-19 | — | — | US | disclosed |
| CN-120152972-A | Thiadiazole derivative, composition and application thereof | 北京丹擎医药科技有限公司 | 2025-06-13 | — | — | CN | disclosed |
| WO-2025119195-A1 | COMBINATION OF POLQ INHIBITOR AND ANTI-CANCER THERAPEUTIC AGENT | DANATLAS PHARMACEUTICALS CO., LTD. (CN) | 2025-06-12 | — | — | WO | disclosed |
| US-20250179068-A1 | SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. (US) | 2025-06-05 | — | — | US | disclosed |
| CN-120077028-A | Thiadiazole derivative, composition and application thereof | 北京丹擎医药科技有限公司 | 2025-05-30 | — | — | CN | disclosed |
| US-20250169514-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2025-05-29 | — | — | US | disclosed |
| CN-114728960-B | Improved synthesis of KRAS G12C inhibitor compounds | 美国安进公司 | 2025-05-27 | — | — | CN | disclosed |
| US-20250163032-A1 | NOVEL MOLECULES AS INHIBITORS OF DNA DAMAGE REPAIR PATHWAY | VRISE THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| WO-2025102016-A1 | NOVEL MOLECULES AS INHIBITORS OF DNA DAMAGE REPAIR PATHWAY | VRISE THERAPEUTICS, INC. (US) | 2025-05-15 | — | — | WO | disclosed |
| US-12280056-B2 | Combination therapy including a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | AMGEN INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-20250122174-A1 | Heteroaryl Compounds As HPK1 Inhibitors And Methods Of Using Same | SHENZHEN YUANLI SHENWAN INNOVATIVE MEDICINE CO LTD (CN) | 2025-04-17 | — | — | US | disclosed |
| CN-119823119-A | Pol theta inhibitor and preparation method, pharmaceutical composition and application thereof | 中国药科大学 | 2025-04-15 | — | — | CN | disclosed |
| US-12264159-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| EP-4524137-A2 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1 | Icahn School of Medicine at Mount Sinai (US) | 2025-03-19 | — | — | EP | disclosed |
| CN-119638694-A | Improved synthesis of key intermediates for KRAS G12C inhibitor compounds | 美国安进公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-119638693-A | Improved synthesis of key intermediates for KRAS G12C inhibitor compounds | 美国安进公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-115057872-B | Substituted heterocyclo-cyclic compounds, preparation and pharmaceutical use thereof | 劲方医药科技(上海)股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| US-12247021-B2 | Substituted tetrahydrofurans as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-03-11 | — | — | US | disclosed |
| US-12240846-B2 | 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases | ENLIVEN INC. (US) | 2025-03-04 | — | — | US | disclosed |
| US-12234244-B2 | Substituted piperazines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2025-02-25 | — | — | US | disclosed |
| US-12232516-B2 | Materials and methods for extending shelf-life of foods | JP LABORATORIES, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| US-20250057817-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2025-02-20 | — | — | US | disclosed |
| CN-113015724-B | Improved synthesis of key intermediates for KRAS G12C inhibitor compounds | 美国安进公司 | 2025-02-18 | — | — | CN | disclosed |
| US-20250051333-A1 | POLYMORPH OF KRAS INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2025-02-13 | — | — | US | disclosed |
| EP-4506001-A2 | SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2025-02-12 | — | — | EP | disclosed |
| US-12221416-B2 | Antagonists of human integrin α4β7 | MORPHIC THERAPEUTIC, INC. (US) | 2025-02-11 | — | — | US | disclosed |
| CN-119365192-A | Heteroaryl compounds as HPK1 inhibitors and methods of use thereof | 深圳市原力深湾创新药有限公司 | 2025-01-24 | — | — | CN | disclosed |
| US-20250026766-A1 | Thiazolopyridyl Amide Derivatives as DNA Polymerase Theta Inhibitors | BEIGENE, LTD. (KY) | 2025-01-23 | — | — | US | disclosed |
| US-12193465-B2 | Materials and methods for extending shelf-life of foods | JP LABORATORIES, INC. (US) | 2025-01-14 | — | — | US | disclosed |
| EP-3965824-B1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1 | ICAHN SCHOOL MED MOUNT SINAI (US) | 2025-01-08 | — | — | EP | disclosed |
| WO-2024253416-A1 | PYRIMIDINE/PYRIDINE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2024-12-12 | — | — | WO | disclosed |
| WO-2024245310-A1 | THIAZOLYL OR THIADIAZOLYL AMIDES DERIVATIVES AND USE THEREOF | NINGBO NEWBAY TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2024-12-05 | — | — | WO | disclosed |
| US-20240391907-A1 | SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-11-28 | — | — | US | disclosed |
| CN-119019388-A | 5-And 6-azaindole compounds for inhibiting Bcr-Abl tyrosine kinase | 英莱汶公司 | 2024-11-26 | — | — | CN | disclosed |
| CN-118994158-A | Nitrogen-containing heterocyclic compound, preparation method and application | 如东凌达生物医药科技有限公司 | 2024-11-22 | — | — | CN | disclosed |
| US-20240383889-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2024-11-21 | — | — | US | disclosed |
| US-20240383862-A1 | COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2024-11-21 | — | — | US | disclosed |
| EP-4463150-A1 | HETEROARYL COMPOUNDS AS HPK1 INHIBITORS AND METHODS OF USING SAME | Shenzhen Ionova Life Science Co., Ltd. (CN) | 2024-11-20 | — | — | EP | disclosed |
| EP-4463456-A1 | THIAZOLOPYRIDYL AMIDE DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | BeiGene, Ltd. (KY) | 2024-11-20 | — | — | EP | disclosed |
| CN-114945566-B | Substituted tetrahydrofurans as sodium channel modulators | 沃泰克斯药物股份有限公司 | 2024-11-12 | — | — | CN | disclosed |
| CN-118908962-A | Heterobifunctional compounds as degradation agents for HPK1 | 西奈山伊坎医学院 | 2024-11-08 | — | — | CN | disclosed |
| WO-2024222712-A1 | IMIDAZOPYRIDINE OR IMIDAZOPYRAZINE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 上海赛默罗生物科技有限公司 | 2024-10-31 | — | — | WO | disclosed |
| EP-4455147-A1 | POLYMORPH OF KRAS INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2024-10-30 | — | — | EP | disclosed |
| US-20240352028-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2024-10-24 | — | — | US | disclosed |
| WO-2024217500-A1 | ISOQUINOLINE COMPOUND, AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 上海赛默罗生物科技有限公司 | 2024-10-24 | — | — | WO | disclosed |
| EP-3492461-B1 | NITROGENOUS HETEROCYCLIC AROMATIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION THEREOF | SHANGHAI YINGLI PHARM CO LTD (CN) | 2024-10-23 | — | — | EP | disclosed |
| EP-4053118-B1 | SUBSTITUTED HETEROCYCLIC FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | GENFLEET THERAPEUTICS SHANGHAI INC (CN) | 2024-10-09 | — | — | EP | disclosed |
| CN-118745177-A | Nitrogen-containing heterocyclic derivative regulator, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-10-08 | — | — | CN | disclosed |
| CN-118745176-A | Nitrogen-containing heterocyclic derivative regulator, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-10-08 | — | — | CN | disclosed |
| US-12103934-B2 | Heterocyclic compound, organic light emitting diode comprising same, composition for organic layer of organic light emitting diode, and method for manufacturing organic light emitting diode | LT MATERIALS CO., LTD. (KR) | 2024-10-01 | — | — | US | disclosed |
| CN-118684631-A | External nucleotide pyrophosphatase/phosphodiesterase 1 (ENPP 1) inhibitors, compositions and uses thereof | 中国科学院上海药物研究所 | 2024-09-24 | — | — | CN | disclosed |
| EP-4069691-B1 | SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMA (US) | 2024-09-18 | — | — | EP | disclosed |
| US-20240294475-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. | 2024-09-05 | — | — | US | disclosed |
| US-20240287080-A1 | O-LINKED THIADIAZOLYL COMPOUNDS AS DNA POLYMERASE THETA INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.4) LIMITED (GB) | 2024-08-29 | — | — | US | disclosed |
| US-20240287059-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2024-08-29 | — | — | US | disclosed |
| US-20240287086-A1 | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2024-08-29 | — | — | US | disclosed |
| CN-113038953-B | Including KRAS for the treatment of cancerG12CCombination therapy of an inhibitor and one or more other pharmaceutically active agents | 美国安进公司 | 2024-08-23 | — | — | CN | disclosed |
| CN-118515663-A | Imidazopyridine or imidazopyrazine compounds, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2024-08-20 | — | — | CN | disclosed |
| CN-118510778-A | Thiazolopyridylamide derivatives as inhibitors of DNA polymerase θ | 百济神州有限公司 | 2024-08-16 | — | — | CN | disclosed |
| US-20240262828-A1 | Functionalized Heterocycles as Antiviral Agents | ENANTA PHARM INC (US) | 2024-08-08 | — | — | US | disclosed |
| CN-118451081-A | Polymorphs of KRAS inhibitors, methods of making and uses thereof | 劲方医药科技(上海)有限公司 | 2024-08-06 | — | — | CN | disclosed |
| US-12054497-B2 | Substituted heterocyclic fused cyclic compound, preparation method therefor and pharmaceutical use thereof | Genfleet Therapeutics (Shanghai)Inc. (CN) | 2024-08-06 | — | — | US | disclosed |
| CN-115626923-B | KRAS G12C inhibitors and methods of use thereof | 美国安进公司 | 2024-08-02 | — | — | CN | disclosed |
| CN-113423703-B | Nitrogen-containing heterocyclic derivative regulator, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-08-02 | — | — | CN | disclosed |
| US-20240254150-A1 | CONFORMATIONALLY RESTRICTED SULFONATE BASED PHOSPHINE LIGANDS FOR HINDERED SUZUKI COUPLING REACTIONS | TCG GreenChem Inc. (US) | 2024-08-01 | — | — | US | disclosed |
| US-20240245686-A1 | COMBINATION THERAPY INCLUDING A KRAS G12C INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS | AMGEN INC. (US) | 2024-07-25 | — | — | US | disclosed |
| CN-118359538-A | Isoquinoline compound, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2024-07-19 | — | — | CN | disclosed |
| CN-113508118-B | Fused tricyclic compounds useful as anticancer agents | 阿斯利康(瑞典)有限公司 | 2024-07-19 | — | — | CN | disclosed |
| CN-112920183-B | Compounds as KRAS-G12C inhibitors and uses thereof | 南京圣和药业股份有限公司 | 2024-07-19 | — | — | CN | disclosed |
| US-20240239767-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-07-18 | — | — | US | disclosed |
| US-20240228469-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-07-11 | — | — | US | disclosed |
| WO-2024126773-A1 | IMIDAZO[4,5-B]PYRIDINE DERIVATIVES AS PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-06-20 | — | — | WO | disclosed |
| CN-113396147-B | Aromatic heterocyclic derivative regulator, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-118184669-A | Macrocyclic compounds as multi-target kinase inhibitors | 北京伯汇生物技术有限公司 | 2024-06-14 | — | — | CN | disclosed |
| US-20240190871-A1 | KRASG12D INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | YA THERAPEUTICS INC (CN) | 2024-06-13 | — | — | US | disclosed |
| US-20240174660-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2024-05-30 | — | — | US | disclosed |
| US-20240173328-A1 | COMBINATION THERAPY INCLUDING A KRAS G12C INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS | AMGEN INC. (US) | 2024-05-30 | — | — | US | disclosed |
| CN-118055930-A | Thiadiazole derivative, composition and application thereof | 北京丹擎医药科技有限公司 | 2024-05-17 | — | — | CN | disclosed |
| WO-2024099336-A1 | THIADIAZOLYL DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO., LTD. (CN) | 2024-05-16 | — | — | WO | disclosed |
| WO-2024099337-A1 | THIADIAZOLYL DERIVATIVES, COMPOSITIONS, AND USES THEREOF | DANATLAS PHARMACEUTICALS CO., LTD. (CN) | 2024-05-16 | — | — | WO | disclosed |
| US-20240158417-A1 | SUBSTITUTED HETEROCYCLIC FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2024-05-16 | — | — | US | disclosed |
| EP-4367117-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | Incyte Corporation (US) | 2024-05-15 | — | — | EP | disclosed |
| US-20240150326-A1 | CARBOXAMIDE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2024-05-09 | — | — | US | disclosed |
| EP-4363406-A1 | NLRP3 INFLAMMASOME INHIBITORS | Astrazeneca AB (SE) | 2024-05-08 | — | — | EP | disclosed |
| US-11970463-B2 | Compounds and their use | ASTRAZENECA AB (SE) | 2024-04-30 | — | — | US | disclosed |
| WO-2024081385-A1 | HPK1 INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| EP-4352055-A1 | O-LINKED THIADIAZOLYL COMPOUNDS AS DNA POLYMERASE THETA INHIBITORS | Ideaya Biosciences, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| CN-117881680-A | Tricyclic compounds as KRAS inhibitors | 因赛特公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-112292380-B | N- (phenyl) -2- (phenyl) pyrimidine-4-carboxamide derivatives and related compounds as HPK1 inhibitors for the treatment of cancer | 因赛特公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-117794927-A | O-linked thiadiazolyl compounds as inhibitors of DNA polymerase theta | 伊迪亚生物科学有限公司 | 2024-03-29 | — | — | CN | disclosed |
| WO-2024062090-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-03-28 | — | — | WO | disclosed |
| CN-117751104-A | Compound with kinase inhibition function and preparation and application thereof | 轶诺(浙江)药业有限公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-117683020-A | Aminopyridine compound of phthalazinone, preparation method thereof and application thereof in preparation of inhibitor and antitumor drug | 华南理工大学 | 2024-03-12 | — | — | CN | disclosed |
| CN-117645614-A | Substituted heterocyclo-cyclic compounds, preparation and pharmaceutical use thereof | 劲方医药科技(上海)有限公司 | 2024-03-05 | — | — | CN | disclosed |
| US-11919887-B2 | Substituted tetrahydrofurans as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-03-05 | — | — | US | disclosed |
| US-11918584-B2 | Combination therapy including a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | AMGEN INC. (US) | 2024-03-05 | — | — | US | disclosed |
| WO-2024044098-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| EP-4328229-A2 | SUBSTITUTED HETEROCYCLIC FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2024-02-28 | — | — | EP | disclosed |
| EP-4328229-A2 | SUBSTITUTED HETEROCYCLIC FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2024-02-28 | — | — | EP | disclosed |
| CN-117229260-B | Double-target inhibitor of DNA polymerase theta and poly ADP ribose polymerase 1, preparation method and medical application thereof | 中国药科大学 | 2024-02-27 | — | — | CN | disclosed |
| CN-114269735-B | Dihydro-or tetrahydroquinazoline compound, intermediate thereof, preparation method and application | 南京创济生物医药有限公司 | 2024-02-23 | — | — | CN | disclosed |
| CN-117580826-A | NLRP3 inflammation corpuscle inhibitor | 阿斯利康(瑞典)有限公司 | 2024-02-20 | — | — | CN | disclosed |
| US-11905281-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2024-02-20 | — | — | US | disclosed |
| CN-113767106-B | Oxazaquinazolin-7 (8H) -ones, preparation method and medical application thereof | 劲方医药科技(上海)有限公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-115551867-B | Fused tricyclic compounds, pharmaceutical compositions and uses thereof | 劲方医药科技(上海)有限公司 | 2024-02-20 | — | — | CN | disclosed |
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2024-02-15 | — | — | US | disclosed |
| US-11897891-B2 | Tricyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2024-02-13 | — | — | US | disclosed |
| US-20240043420-A1 | 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2024-02-08 | — | — | US | disclosed |
| US-20240043441-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2024-02-08 | — | — | US | disclosed |
| US-11891393-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-02-06 | — | — | US | disclosed |
| US-11891388-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2024-02-06 | — | — | US | disclosed |
| US-11878985-B2 | Substituted quinazolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2024-01-23 | — | — | US | disclosed |
| US-20240023359-A1 | ORGANIC LIGHT-EMITTING DEVICE COMPRISING NOVEL ORGANIC COMPOUND IN EMISSION LAYER | SFC CO., LTD. (KR) | 2024-01-18 | — | — | US | disclosed |
| US-20240023359-A1 | ORGANIC LIGHT-EMITTING DEVICE COMPRISING NOVEL ORGANIC COMPOUND IN EMISSION LAYER | SFC CO., LTD. (KR) | 2024-01-18 | — | — | US | disclosed |
| US-20240016058-A1 | NOVEL ORGANIC COMPOUND, AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | SFC CO., LTD. (KR) | 2024-01-11 | — | — | US | disclosed |
| US-11866426-B2 | Benzothiazole compounds and uses thereof | INCYTE CORPORATION (US) | 2024-01-09 | — | — | US | disclosed |
| US-20230416232-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF | BLUEPRINT MEDICINES CORPORATION | 2023-12-28 | — | — | US | disclosed |
| CN-112552294-B | Piperazine heterocyclic derivative-containing inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-12-19 | — | — | CN | disclosed |
| CN-117229260-A | Double-target inhibitor of DNA polymerase theta and poly ADP ribose polymerase 1, preparation method and medical application thereof | 中国药科大学 | 2023-12-15 | — | — | CN | disclosed |
| US-20230399327-A1 | HIGH ACTIVITY HPK1 KINASE INHIBITOR | ADLAI NORTYE BIOPHARMA CO., LTD. (CN) | 2023-12-14 | — | — | US | disclosed |
| CN-117222646-A | KRAS G12C inhibitors and uses thereof | 苏州赞荣医药科技有限公司 | 2023-12-12 | — | — | CN | disclosed |
| US-11834441-B2 | Substituted tetrahydrofurans as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230382907-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230382907-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230382907-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230380457-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2023-11-30 | — | — | US | disclosed |
| EP-4280882-A2 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. (US) | 2023-11-29 | — | — | EP | disclosed |
| CN-117083271-A | Substituted thiadiazolyl derivatives as DNA polymerase theta inhibitors | 伊迪亚生物科学有限公司 | 2023-11-17 | — | — | CN | disclosed |
| US-20230363426-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2023-11-16 | — | — | US | disclosed |
| EP-3935060-B1 | FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2023-11-15 | — | — | EP | disclosed |
| CN-113061132-B | Condensed ring lactam compound, preparation method and application | 上海凌达生物医药有限公司 | 2023-11-14 | — | — | CN | disclosed |
| EP-3976608-B1 | THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES INC (US) | 2023-11-08 | — | — | EP | disclosed |
| US-11807638-B2 | 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases | ENLIVEN INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807638-B2 | 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases | ENLIVEN INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807638-B2 | 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases | ENLIVEN INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11795166-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2023-10-24 | — | — | US | disclosed |
| US-11793220-B2 | Materials and methods for extending shelf-life of foods | JP LABORATORIES, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| CN-116916755-A | Materials and methods for extending the shelf life of food products | JP实验室公司 | 2023-10-20 | — | — | CN | disclosed |
| EP-4255573-A1 | SUBSTITUTED THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | Ideaya Biosciences, Inc. (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-3788038-B1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-4254526-A1 | ORGANIC LIGHT-EMITTING DEVICE COMPRISING NOVEL ORGANIC COMPOUND IN EMISSION LAYER | SFC Co., Ltd. (KR) | 2023-10-04 | — | — | EP | disclosed |
| EP-4253371-A1 | NOVEL ORGANIC COMPOUND, AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | SFC Co., Ltd. (KR) | 2023-10-04 | — | — | EP | disclosed |
| CN-116848111-A | KRAS inhibitor key intermediate and preparation method thereof | 浙江海正药业股份有限公司 | 2023-10-03 | — | — | CN | disclosed |
| CN-116829557-A | Pentaheterocycle compound, preparation method and application thereof | 上海艾力斯医药科技股份有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-09-28 | — | — | US | disclosed |
| WO-2023183405-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| US-11767321-B2 | 5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases | ENLIVEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767321-B2 | 5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases | ENLIVEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767321-B2 | 5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases | ENLIVEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230295163-A1 | TETRACYCLIC DERIVATIVE, METHOD FOR PREPARING SAME AND USE THEREOF IN MEDICINE | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2023-09-21 | — | — | US | disclosed |
| US-20230295163-A1 | TETRACYCLIC DERIVATIVE, METHOD FOR PREPARING SAME AND USE THEREOF IN MEDICINE | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2023-09-21 | — | — | US | disclosed |
| US-20230295163-A1 | TETRACYCLIC DERIVATIVE, METHOD FOR PREPARING SAME AND USE THEREOF IN MEDICINE | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2023-09-21 | — | — | US | disclosed |
| CN-114761408-B | KRAS G12C inhibitor and application thereof in medicine | 贝达药业股份有限公司 | 2023-09-15 | — | — | CN | disclosed |
| US-20230286961-A1 | SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2023-09-14 | — | — | US | disclosed |
| EP-3262036-B1 | THERAPEUTIC PYRIDAZINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2023-09-13 | — | — | EP | disclosed |
| EP-4237088-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF | Blueprint Medicines Corporation (US) | 2023-09-06 | — | — | EP | disclosed |
| CN-116710444-A | Pyrimidine compounds, compositions and pharmaceutical uses thereof | 缆图药品公司 | 2023-09-05 | — | — | CN | disclosed |
| CN-116685585-A | High-activity HPK1 kinase inhibitor | 杭州阿诺生物医药科技有限公司 | 2023-09-01 | — | — | CN | disclosed |
| EP-4234546-A2 | IMPROVED SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | Amgen Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4234546-A2 | IMPROVED SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | Amgen Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-11737481-B2 | Materials and methods for extending shelf-life of foods | JP LABORATORIES, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| CN-116648453-A | 5-and 6-azaindole compounds for inhibiting Bcr-Abl tyrosine kinase | 活力疗法公司 | 2023-08-25 | — | — | CN | disclosed |
| US-11731958-B2 | Carboxamide compounds and uses thereof | INCYTE CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
| CN-112390818-B | Substituted heteroaromatic dihydro pyrimidinone derivatives, their preparation and pharmaceutical use | 劲方医药科技(上海)有限公司 | 2023-08-22 | — | — | CN | disclosed |
| CN-116621833-A | KRAS G12C inhibitors and methods of use thereof | 美国安进公司 | 2023-08-22 | — | — | CN | disclosed |
| CN-116606261-A | KRAS G12C inhibitors and methods of use thereof | 美国安进公司 | 2023-08-18 | — | — | CN | disclosed |
| EP-4225742-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | Enliven Therapeutics, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-4225741-A1 | 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | Enliven Therapeutics, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| CN-116529244-A | Novel organic compound and organic light-emitting element comprising same | SFC株式会社 | 2023-08-01 | — | — | CN | disclosed |
| CN-116491242-A | Organic light-emitting element comprising novel organic compound in light-emitting layer | SFC株式会社 | 2023-07-25 | — | — | CN | disclosed |
| WO-2023134708-A1 | THIAZOLOPYRIDYL AMIDE DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | BEIGENE , LTD. (KY) | 2023-07-20 | — | — | WO | disclosed |
| US-20230227472-A1 | FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20230227472-A1 | FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD (CN) | 2023-07-20 | — | — | US | disclosed |
| WO-2023137406-A1 | HETEROARYL COMPOUNDS AS HPK1 INHIBITORS AND METHODS OF USING SAME | SHENZHEN IONOVA LIFE SCIENCE CO., LTD. (CN) | 2023-07-20 | — | — | WO | disclosed |
| WO-2023137406-A1 | HETEROARYL COMPOUNDS AS HPK1 INHIBITORS AND METHODS OF USING SAME | SHENZHEN IONOVA LIFE SCIENCE CO., LTD. (CN) | 2023-07-20 | — | — | WO | disclosed |
| CN-112851663-B | Parallel heterocyclic compound and application thereof | 博瑞生物医药（苏州）股份有限公司 | 2023-07-18 | — | — | CN | disclosed |
| CN-116438182-A | 7-azaindole compounds for inhibiting BCR-ABL tyrosine kinase | 活力疗法公司 | 2023-07-14 | — | — | CN | disclosed |
| CN-116406363-A | Tetracyclic derivative, preparation method and medical application thereof | 浙江海正药业股份有限公司 | 2023-07-07 | — | — | CN | disclosed |
| US-20230212183-A9 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230212183-A9 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-07-06 | — | — | US | disclosed |
| CN-116375746-A | Preparation method of (2-fluoro-6-hydroxyphenyl) potassium trifluoroborate | 上海馨远医药科技有限公司 | 2023-07-04 | — | — | CN | disclosed |
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-06-29 | — | — | US | disclosed |
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-06-29 | — | — | US | disclosed |
| WO-2023116895-A1 | POLYMORPH OF KRAS INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 劲方医药科技(上海)有限公司 | 2023-06-29 | — | — | WO | disclosed |
| US-20230192681-A1 | IMPROVED SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230192681-A1 | IMPROVED SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230192681-A1 | IMPROVED SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230192696-A1 | SPIRO COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION | 2023-06-22 | — | — | US | disclosed |
| EP-3880670-B1 | IMPROVED SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-3880670-B1 | IMPROVED SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC (US) | 2023-06-07 | — | — | EP | disclosed |
| CN-116199636-A | 2, 4-disubstituted pyrimidine derivative of targeted tumor immunity kinase, preparation method and application thereof | 杭州医学院 | 2023-06-02 | — | — | CN | disclosed |
| EP-3564233-B1 | 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | NOVARTIS AG (CH) | 2023-05-03 | — | — | EP | disclosed |
| US-20230130724-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230130724-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230130724-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2023-04-27 | — | — | US | disclosed |
| WO-2023067515-A1 | THIADIAZOLYL COMPOUNDS AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| US-20230121955-A1 | COMBINATION THERAPY INCLUDING A KRAS G12C INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS | AMGEN INC. (US) | 2023-04-20 | — | — | US | disclosed |
| US-20230121955-A1 | COMBINATION THERAPY INCLUDING A KRAS G12C INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS | AMGEN INC. (US) | 2023-04-20 | — | — | US | disclosed |
| WO-2023061415-A1 | THIADIAZOLYL DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO., LTD. (CN) | 2023-04-20 | — | — | WO | disclosed |
| US-20230110122-A1 | COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-04-13 | — | — | US | disclosed |
| EP-4159739-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2023-04-05 | — | — | EP | disclosed |
| WO-2023040989-A1 | KRAS G12C INHIBITORS AND USES THEREOF | SUZHOU ZANRONG PHARMA LIMITED (CN) | 2023-03-23 | — | — | WO | disclosed |
| CN-115819417-A | Pyrazolopyridine derivatives as HPK1 modulators and their use for the treatment of cancer | 因赛特公司 | 2023-03-21 | — | — | CN | disclosed |
| US-20230078112-A1 | THIADIAZOLYL DERIVATIVES | IDEAYA BIOSCIENCES, INC. | 2023-03-16 | — | — | US | disclosed |
| US-20230084095-A1 | SUBSTITUTED HETEROCYCLIC FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-03-16 | — | — | US | disclosed |
| US-20230075366-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2023-03-09 | — | — | US | disclosed |
| US-20230062486-A1 | KRAS G12C INHIBITOR AND PHARMACEUTICAL USE THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2023-03-02 | — | — | US | disclosed |
| US-20230065635-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2023-03-02 | — | — | US | disclosed |
| CN-113861188-B | Pyrazolo [3,4-b ] pyridine derivative, preparation method thereof and application thereof as HPK1 inhibitor | 杭州医学院 | 2023-02-28 | — | — | CN | disclosed |
| US-20230056631-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION | 2023-02-23 | — | — | US | disclosed |
| US-20230026856-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SPARCBIO LLC | 2023-01-26 | — | — | US | disclosed |
| US-20230022524-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1 | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2023-01-26 | — | — | US | disclosed |
| US-20230022524-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1 | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2023-01-26 | — | — | US | disclosed |
| US-20230026856-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SPARCBIO LLC | 2023-01-26 | — | — | US | disclosed |
| CN-115626923-A | KRAS G12C inhibitors and methods of use thereof | 美国安进公司 | 2023-01-20 | — | — | CN | disclosed |
| EP-4119558-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | Incyte Corporation (US) | 2023-01-18 | — | — | EP | disclosed |
| CN-115611898-A | Tetracyclic derivative, preparation method and medical application thereof | 浙江海正药业股份有限公司 | 2023-01-17 | — | — | CN | disclosed |
| US-20230009626-A1 | INDOLINONE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | ICHNOS SCIENCES S.A. (CH) | 2023-01-12 | — | — | US | disclosed |
| WO-2023283213-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION (US) | 2023-01-12 | — | — | WO | disclosed |
| WO-2023275366-A1 | NLRP3 INFLAMMASOME INHIBITORS | ASTRAZENECA AB (SE) | 2023-01-05 | — | — | WO | disclosed |
| US-20230002371-A1 | RAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX INC (US) | 2023-01-05 | — | — | US | disclosed |
| US-11542265-B2 | Pyrazolopyrimidine compounds and uses thereof | INCYTE CORPORATION (US) | 2023-01-03 | — | — | US | disclosed |
| CN-115557946-A | Heterocyclic lactam compound, pharmaceutical composition containing same and application thereof | 四川科伦博泰生物医药股份有限公司 | 2023-01-03 | — | — | CN | disclosed |
| CN-115551867-A | Fused tricyclic compound, pharmaceutical composition and application thereof | 劲方医药科技(上海)有限公司 | 2022-12-30 | — | — | CN | disclosed |
| US-20220402907-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | YALE UNIVERSITY | 2022-12-22 | — | — | US | disclosed |
| US-11530218-B2 | Spiro compounds as inhibitors of KRAS | INCYTE CORPORATION (US) | 2022-12-20 | — | — | US | disclosed |
| WO-2022259204-A1 | O-LINKED THIADIAZOLYL COMPOUNDS AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| US-20220395504-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2022-12-15 | — | — | US | disclosed |
| EP-4101852-A1 | PYRIDOPYRIMIDINONE COMPOUND AND APPLICATION THEREOF | Bebetter Med Inc. (CN) | 2022-12-14 | — | — | EP | disclosed |
| EP-4101849-A1 | 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | Novartis AG (CH) | 2022-12-14 | — | — | EP | disclosed |
| WO-2022253328-A1 | COMPOUND HAVING KINASE INHIBITORY FUNCTION, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 轶诺(浙江)药业有限公司 | 2022-12-08 | — | — | WO | disclosed |
| US-20220389029-A1 | FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD (CN) | 2022-12-08 | — | — | US | disclosed |
| US-20220387428-A1 | 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | NOVARTIS AG (CH) | 2022-12-08 | — | — | US | disclosed |
| CN-115433161-A | Novel HPK1 inhibitor and preparation method and application thereof | 轶诺(浙江)药业有限公司 | 2022-12-06 | — | — | CN | disclosed |
| US-11492354-B2 | Indazole compounds and uses thereof | INCYTE CORPORATION (US) | 2022-11-08 | — | — | US | disclosed |
| CN-109923114-B | Pyrazolopyridine derivatives as HPK1 modulators and their use for the treatment of cancer | 因赛特公司 | 2022-11-01 | — | — | CN | disclosed |
| CN-110997668-B | KRAS G12C inhibitors and methods of use thereof | 美国安进公司 | 2022-11-01 | — | — | CN | disclosed |
| US-20220340529-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. | 2022-10-27 | — | — | US | disclosed |
| WO-2022223037-A1 | SALT OR POLYMORPH OF KRAS INHIBITOR | 劲方医药科技(上海)有限公司 | 2022-10-27 | — | — | WO | disclosed |
| CN-115197132-A | HPK1 inhibitor and application thereof in medicine | 贝达药业股份有限公司 | 2022-10-18 | — | — | CN | disclosed |
| EP-4069691-A1 | SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2022-10-12 | — | — | EP | disclosed |
| US-11466003-B2 | Nitrogenous heterocyclic aromatic compound, preparation method therefor, pharmaceutical composition thereof, and application thereof | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) | 2022-10-11 | — | — | US | disclosed |
| CN-115124533-A | Tetracyclic derivative, preparation method and medical application thereof | 浙江海正药业股份有限公司 | 2022-09-30 | — | — | CN | disclosed |
| WO-2022199170-A1 | TETRACYCLIC DERIVATIVE, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 浙江海正药业股份有限公司 | 2022-09-29 | — | — | WO | disclosed |
| WO-2022198904-A1 | KEY INTERMEDIATE OF KRAS INHIBITOR AND PREPARATION METHOD THEREFOR | 浙江海正药业股份有限公司 | 2022-09-29 | — | — | WO | disclosed |
| US-20220298174-A1 | TETRACYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD (CN) | 2022-09-22 | — | — | US | disclosed |
| EP-4058453-A1 | IMPROVED SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | Amgen Inc. (US) | 2022-09-21 | — | — | EP | disclosed |
| CN-115073450-A | KRAS G12C Preparation and application of mutant protein inhibitor | 药雅科技(上海)有限公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-115073451-A | KRAS G12D Preparation and application of mutant protein inhibitor | 药雅科技(上海)有限公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-115057872-A | Substituted heterocyclic ring compound, preparation method and medical application thereof | 劲方医药科技(上海)有限公司 | 2022-09-16 | — | — | CN | disclosed |
| US-11439645-B2 | Combination therapy including a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | AMGEN INC. (US) | 2022-09-13 | — | — | US | disclosed |
| EP-4053118-A1 | SUBSTITUTED HETEROCYCLIC FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2022-09-07 | — | — | EP | disclosed |
| CN-114945566-A | Substituted tetrahydrofurans as sodium channel modulators | 沃泰克斯药物股份有限公司 | 2022-08-26 | — | — | CN | disclosed |
| US-20220267322-A1 | OXAZOLE COMPOUND AS MULTI-TARGETED INHIBITOR OF IRAK4 AND BTK | Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. (CN) | 2022-08-25 | — | — | US | disclosed |
| US-20220264914-A1 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. | 2022-08-25 | — | — | US | disclosed |
| CN-112047948-B | Kras mutant inhibitors | 山东轩竹医药科技有限公司 | 2022-08-16 | — | — | CN | disclosed |
| US-20220251109-A1 | OXAAZAQUINAZOLINE-7(8H)-KETONE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2022-08-11 | — | — | US | disclosed |
| CN-113853373-B | Substituted heterocyclic ring compound, preparation method and medical application thereof | 劲方医药科技(上海)有限公司 | 2022-08-05 | — | — | CN | disclosed |
| US-20220242875-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2022-08-04 | — | — | US | disclosed |
| WO-2022161489-A1 | PENTAHETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海艾力斯医药科技股份有限公司 | 2022-08-04 | — | — | WO | disclosed |
| CN-111662232-B | Small molecule compound with 2H-indazole structure and synthesis and application thereof | 中国科学院上海药物研究所 | 2022-08-02 | — | — | CN | disclosed |
| CN-113354651-B | Pyrazolo [1,5-a ] quinazoline derivative and application thereof in preparation of medicines | 四川大学 | 2022-07-22 | — | — | CN | disclosed |
| US-20220225646-A1 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. | 2022-07-21 | — | — | US | disclosed |
| US-20220225647-A1 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. | 2022-07-21 | — | — | US | disclosed |
| US-20220227752-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2022-07-21 | — | — | US | disclosed |
| CN-114761408-A | KRAS G12C inhibitor and application thereof in medicines | 贝达药业股份有限公司 | 2022-07-15 | — | — | CN | disclosed |
| US-20220220112-A1 | SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. | 2022-07-14 | — | — | US | disclosed |
| US-20220220112-A1 | SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. | 2022-07-14 | — | — | US | disclosed |
| CN-108602806-B | Improved apelin receptor (APJ) agonists and uses thereof | 研究三角协会 | 2022-07-12 | — | — | CN | disclosed |
| CN-114728960-A | Improved synthesis of KRAS G12C inhibitor compounds | 美国安进公司 | 2022-07-08 | — | — | CN | disclosed |
| US-20220213100-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2022-07-07 | — | — | US | disclosed |
| EP-3510032-B1 | PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER | INCYTE CORP (US) | 2022-07-06 | — | — | EP | disclosed |
| CN-111217843-B | Method for synthesizing 2-fluoro-6-hydroxyphenylboronic acid | 大连联化化学有限公司 | 2022-07-01 | — | — | CN | disclosed |
| US-20220204527-A1 | FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS | ASTRAZENECA UK LIMITED (GB) | 2022-06-30 | — | — | US | disclosed |
| WO-2022127847-A1 | PYRIMIDONE DERIVATIVE AND APPLICATION THEREOF IN DRUG | 广东东阳光药业有限公司 | 2022-06-23 | — | — | WO | disclosed |
| CN-114644628-A | Pyrimidone derivatives and their use in medicine | 广东东阳光药业有限公司 | 2022-06-21 | — | — | CN | disclosed |
| EP-4011886-A1 | TETRACYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Jemincare Pharmaceuticals Co., Ltd. (CN) | 2022-06-15 | — | — | EP | disclosed |
| WO-2022118210-A1 | SUBSTITUTED THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2022-06-09 | — | — | WO | disclosed |
| US-20220168280-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2022-06-02 | — | — | US | disclosed |
| WO-2022114448-A1 | ORGANIC LIGHT-EMITTING DEVICE COMPRISING NOVEL ORGANIC COMPOUND IN EMISSION LAYER | 에스에프씨 주식회사 | 2022-06-02 | — | — | WO | disclosed |
| WO-2022114444-A1 | NOVEL ORGANIC COMPOUND, AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | 에스에프씨 주식회사 | 2022-06-02 | — | — | WO | disclosed |
| EP-4001269-A1 | BENZOISOTHIAZOLE, ISOTHIAZOLO[3,4-B]PYRIDINE, QUINAZOLINE, PHTHALAZINE, PYRIDO[2,3-D]PYRIDAZINE AND PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS FOR TREATING LUNG, PANCREATIC OR COLORECTAL CANCER | Amgen Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
| US-20220153729-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-05-19 | — | — | US | disclosed |
| EP-3998264-A1 | OXAZOLE COMPOUND AS MULTI-TARGETED INHIBITOR OF IRAK4 AND BTK | Medshine Discovery Inc. (CN) | 2022-05-18 | — | — | EP | disclosed |
| EP-3998264-A1 | OXAZOLE COMPOUND AS MULTI-TARGETED INHIBITOR OF IRAK4 AND BTK | Medshine Discovery Inc. (CN) | 2022-05-18 | — | — | EP | disclosed |
| WO-2022094355-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF | LENGO THERAPEUTICS, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022089398-A1 | HIGH ACTIVITY HPK1 KINASE INHIBITOR | 杭州阿诺生物医药科技有限公司 | 2022-05-05 | — | — | WO | disclosed |
| EP-3755703-B1 | N-(PHENYL)-2-(PHENYL)PYRIMIDINE-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS HPK1 INHIBITORS FOR TREATING CANCER | INCYTE CORP (US) | 2022-05-04 | — | — | EP | disclosed |
| CN-114423463-A | Heterobifunctional compounds as HPK1 degradants | 西奈山伊坎医学院 | 2022-04-29 | — | — | CN | disclosed |
| WO-2022076973-A1 | 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN THERAPEUTICS, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022076975-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN THERAPEUTICS, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022076975-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN THERAPEUTICS, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| US-11299473-B2 | Benzimidazole and indole compounds and uses thereof | INCYTE CORPORATION (US) | 2022-04-12 | — | — | US | disclosed |
| US-11299491-B2 | Synthesis of key intermediate of KRAS G12C inhibitor compound | AMGEN INC. (US) | 2022-04-12 | — | — | US | disclosed |
| US-11299491-B2 | Synthesis of key intermediate of KRAS G12C inhibitor compound | AMGEN INC. (US) | 2022-04-12 | — | — | US | disclosed |
| EP-3978490-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2022-04-06 | — | — | EP | disclosed |
| EP-3976608-A1 | THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | Ideaya Biosciences, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| CN-114269735-A | Dihydro or tetrahydro quinazoline compound and intermediate, preparation method and application thereof | 南京创济生物医药有限公司 | 2022-04-01 | — | — | CN | disclosed |
| EP-3974429-A1 | PRECURSORS OF KRAS G12C INHIBITORS | Amgen Inc. (US) | 2022-03-30 | — | — | EP | disclosed |
| US-11285135-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2022-03-29 | — | — | US | disclosed |
| EP-3964516-A1 | OXAAZAQUINAZOLINE-7(8H)-KETONE COMPOUND, PREPARATION METHOD THERFOR AND PHARMACEUTICAL APPLICATION THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2022-03-09 | — | — | EP | disclosed |
| CN-114127062-A | Thiadiazolyl derivatives as inhibitors of DNA polymerase Theta | 伊迪亚生物科学有限公司 | 2022-03-01 | — | — | CN | disclosed |
| WO-2022037630-A1 | TETRACYCLIC DERIVATIVE, METHOD FOR PREPARING SAME AND USE THEREOF IN MEDICINE | 浙江海正药业股份有限公司 | 2022-02-24 | — | — | WO | disclosed |
| US-11242343-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2022-02-08 | — | — | US | disclosed |
| US-11229648-B2 | 1,4-disubstituted pyridazine analogs thereof and methods for treating SMN-deficiency-related conditions | NOVARTIS AG (CH) | 2022-01-25 | — | — | US | disclosed |
| EP-3935060-A1 | FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS | Astrazeneca AB (SE) | 2022-01-12 | — | — | EP | disclosed |
| CN-113861188-A | Pyrazolo [3,4-b ] pyridine derivative, preparation method thereof and application thereof as HPK1 inhibitor | 杭州医学院 | 2021-12-31 | — | — | CN | disclosed |
| CN-108290838-B | Biaryl derivatives and drugs containing the same | 科研制药株式会社 | 2021-12-31 | — | — | CN | disclosed |
| CN-113853373-A | Substituted heterocyclic ring compound, preparation method and medical application thereof | 劲方医药科技(上海)有限公司 | 2021-12-28 | — | — | CN | disclosed |
| US-20210395263-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT EMITTING DIODE COMPRISING SAME, COMPOSITION FOR ORGANIC LAYER OF ORGANIC LIGHT EMITTING DIODE, AND METHOD FOR MANUFACTURING ORGANIC LIGHT EMITTING DIODE | LT MATERIALS CO., LTD. (KR) | 2021-12-23 | — | — | US | disclosed |
| CN-108026046-B | Substituted quinazoline compounds and their use as inhibitors of G12C mutant KRAS, HRAS and/or NRAS proteins | 亚瑞克西斯制药公司 | 2021-12-21 | — | — | CN | disclosed |
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20210380581-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2021-12-09 | — | — | US | disclosed |
| CN-113767106-A | Oxaazaquinazolin-7 (8H) -ones, their preparation and pharmaceutical use | 劲方医药科技(上海)有限公司 | 2021-12-07 | — | — | CN | disclosed |
| US-20210371425-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2021-12-02 | — | — | US | disclosed |
| WO-2021239058-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 劲方医药科技(上海)有限公司 | 2021-12-02 | — | — | WO | disclosed |
| US-11174228-B2 | Antagonists of human integrin (α4)(β7) | MORPHIC THERAPEUTIC, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-11174228-B2 | Antagonists of human integrin (α4)(β7) | MORPHIC THERAPEUTIC, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-11161841-B2 | Modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| CN-107531668-B | Therapeutic pyridazine compounds and uses thereof | 基因泰克公司 | 2021-10-29 | — | — | CN | disclosed |
| CN-113508118-A | Fused tricyclic compounds useful as anticancer agents | 阿斯利康(瑞典)有限公司 | 2021-10-15 | — | — | CN | disclosed |
| EP-2885288-B1 | 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | NOVARTIS AG (CH) | 2021-10-06 | — | — | EP | disclosed |
| CN-112300173-B | Nitrogen-containing polycyclic compounds, preparation method and application | 上海凌达生物医药有限公司 | 2021-10-01 | — | — | CN | disclosed |
| US-20210300916-A1 | NITROGENOUS HETEROCYCLIC AROMATIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION THEREOF | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) | 2021-09-30 | — | — | US | disclosed |
| EP-3883579-A2 | <SUP2/>? <SUB2/>?G12C? ?COMBINATION THERAPY INCLUDING A KRASINHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS | Amgen Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| EP-3883570-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | Enanta Pharmaceuticals, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| EP-3880670-A1 | IMPROVED SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | Amgen Inc. (US) | 2021-09-22 | — | — | EP | disclosed |
| CN-113423703-A | Nitrogen-containing heterocyclic derivative regulator, and preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2021-09-21 | — | — | CN | disclosed |
| CN-112142735-B | Condensed cyanopyridine compound, preparation method and application | 上海凌达生物医药有限公司 | 2021-09-17 | — | — | CN | disclosed |
| CN-113396147-A | Aromatic heterocyclic derivative regulator, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2021-09-14 | — | — | CN | disclosed |
| CN-112159405-B | Pyridopyrimidinone compounds and application thereof | 广州必贝特医药技术有限公司 | 2021-09-14 | — | — | CN | disclosed |
| CN-113354651-A | Pyrazolo [1,5-a ] quinazoline derivative and application thereof in preparation of medicines | 四川大学 | 2021-09-07 | — | — | CN | disclosed |
| CN-113271946-A | Functionalized heterocyclic compounds as antiviral agents | 英安塔制药有限公司 | 2021-08-17 | — | — | CN | disclosed |
| US-11090304-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2021-08-17 | — | — | US | disclosed |
| EP-3862353-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT EMITTING DIODE COMPRISING SAME, COMPOSITION FOR ORGANIC LAYER OF ORGANIC LIGHT EMITTING DIODE, AND METHOD FOR MANUFACTURING ORGANIC LIGHT EMITTING DIODE | LT Materials Co., Ltd. (KR) | 2021-08-11 | — | — | EP | disclosed |
| EP-3860976-A1 | INDOLINONE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | ICHNOS SCIENCES S.A. (CH) | 2021-08-11 | — | — | EP | disclosed |
| EP-3558955-B1 | BENZISOTHIAZOLE, ISOTHIAZOLO[3,4-B]PYRIDINE, QUINAZOLINE, PHTHALAZINE, PYRIDO[2,3-D]PYRIDAZINE AND PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS FOR TREATING LUNG, PANCREATIC OR COLORECTAL CANCER | AMGEN INC (US) | 2021-08-11 | — | — | EP | disclosed |
| US-11084804-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-08-10 | — | — | US | disclosed |
| CN-113227049-A | Indolinone compounds as MAP4K1 inhibitors | 艾科诺斯科技股份有限公司 | 2021-08-06 | — | — | CN | disclosed |
| US-20210230162-A1 | SPIRO COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION | 2021-07-29 | — | — | US | disclosed |
| WO-2021150613-A1 | SPIRO COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION (US) | 2021-07-29 | — | — | WO | disclosed |
| CN-113061132-A | Condensed ring lactam compound, preparation method and application | 上海凌达生物医药有限公司 | 2021-07-02 | — | — | CN | disclosed |
| US-20210198241-A1 | SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2021-07-01 | — | — | US | disclosed |
| CN-113038953-A | Comprising KRAS for the treatment of cancerG12CCombination therapy of an inhibitor and one or more other pharmaceutically active agents | 美国安进公司 | 2021-06-25 | — | — | CN | disclosed |
| US-20210188869-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2021-06-24 | — | — | US | disclosed |
| US-20210188869-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2021-06-24 | — | — | US | disclosed |
| WO-2021121371-A1 | KRAS G12C INHIBITOR AND PHARMACEUTICAL USE THEREOF | 贝达药业股份有限公司 | 2021-06-24 | — | — | WO | disclosed |
| WO-2021121371-A1 | KRAS G12C INHIBITOR AND PHARMACEUTICAL USE THEREOF | 贝达药业股份有限公司 | 2021-06-24 | — | — | WO | disclosed |
| CN-113015724-A | Improved synthesis of key intermediates of KRAS G12C inhibitor compounds | 美国安进公司 | 2021-06-22 | — | — | CN | disclosed |
| CN-107663206-B | Nitrogen-containing aromatic heterocyclic compound, preparation method thereof, pharmaceutical composition and application thereof | 上海璎黎药业有限公司 | 2021-06-18 | — | — | CN | disclosed |
| WO-2021113479-A1 | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION (US) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021113627-A1 | SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-06-10 | — | — | WO | disclosed |
| US-20210171518-A1 | BENZOTHIAZOLE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2021-06-10 | — | — | US | disclosed |
| US-20210171535-A1 | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2021-06-10 | — | — | US | disclosed |
| US-11021470-B2 | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof | ARAXES PHARMA LLC (US) | 2021-06-01 | — | — | US | disclosed |
| CN-112851663-A | Fused heterocyclic compound and application thereof | 博瑞生物医药（苏州）股份有限公司 | 2021-05-28 | — | — | CN | disclosed |
| US-11014929-B2 | Pyrazolopyrimidine compounds and uses thereof | INCYTE CORPORATION (US) | 2021-05-25 | — | — | US | disclosed |
| WO-2021097212-A1 | IMPROVED SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| WO-2021097212-A1 | IMPROVED SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| CN-112789274-A | Heterocyclic compound, organic light-emitting element including the same, composition for organic layer of organic light-emitting element, and method for manufacturing organic light-emitting element | LT素材株式会社 | 2021-05-11 | — | — | CN | disclosed |
| WO-2021083167-A1 | SUBSTITUTED HETEROCYCLIC FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 劲方医药科技(上海)有限公司 | 2021-05-06 | — | — | WO | disclosed |
| WO-2021083167-A1 | SUBSTITUTED HETEROCYCLIC FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 劲方医药科技(上海)有限公司 | 2021-05-06 | — | — | WO | disclosed |
| US-10975071-B2 | Inhibitors of KRAS G12C mutant proteins | ARAXES PHARMA LLC (US) | 2021-04-13 | — | — | US | disclosed |
| WO-2021063346-A1 | KRAS G12C INHIBITOR AND APPLICATION THEREOF | 上海迪诺医药科技有限公司 | 2021-04-08 | — | — | WO | disclosed |
| US-20210094934-A1 | CARBOXAMIDE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2021-04-01 | — | — | US | disclosed |
| CN-112552294-A | Piperazine heterocyclic derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2021-03-26 | — | — | CN | disclosed |
| WO-2021052499-A1 | FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海济煜医药科技有限公司 | 2021-03-25 | — | — | WO | disclosed |
| WO-2021051034-A1 | RAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2021-03-18 | — | — | WO | disclosed |
| EP-3788038-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | Amgen Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| US-10934288-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2021-03-02 | — | — | US | disclosed |
| CN-112390818-A | Substituted heteroaromatic dihydro pyrimidone derivatives, preparation method and medical application thereof | 劲方医药科技(上海)有限公司 | 2021-02-23 | — | — | CN | disclosed |
| US-10927125-B2 | Substituted cinnolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2021-02-23 | — | — | US | disclosed |
| US-10927125-B2 | Substituted cinnolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2021-02-23 | — | — | US | disclosed |
| EP-3774777-A2 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3773573-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | Morphic Therapeutic, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| WO-2021023154-A1 | TETRACYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海济煜医药科技有限公司 | 2021-02-11 | — | — | WO | disclosed |
| CN-112312910-A | Human integrin alpha 4 beta 7 antagonists | 莫菲克医疗股份有限公司 | 2021-02-02 | — | — | CN | disclosed |
| CN-112292380-A | N- (phenyl) -2- (phenyl) pyrimidine-4-carboxamide derivatives and related compounds as HPK1 inhibitors for the treatment of cancer | 因赛特公司 | 2021-01-29 | — | — | CN | disclosed |
| US-20210024505-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-01-28 | — | — | US | disclosed |
| US-10899755-B2 | Benzothiazole compounds and uses thereof | INCYTE CORPORATION (US) | 2021-01-26 | — | — | US | disclosed |
| WO-2021004533-A1 | OXAZOLE COMPOUND AS MULTI-TARGETED INHIBITOR OF IRAK4 AND BTK | 南京明德新药研发有限公司 | 2021-01-14 | — | — | WO | disclosed |
| US-20210009577-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2021-01-14 | — | — | US | disclosed |
| CN-112218859-A | Modulators of proteolysis and related methods of use | 阿尔维纳斯运营股份有限公司 | 2021-01-12 | — | — | CN | disclosed |
| US-20210002288-A1 | INDAZOLE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2021-01-07 | — | — | US | disclosed |
| CN-108349989-B | Pyrano bipyridine compound | 卫材R&D管理有限公司 | 2021-01-01 | — | — | CN | disclosed |
| CN-112159405-A | Pyridopyrimidinone compounds and application thereof | 广州必贝特医药技术有限公司 | 2021-01-01 | — | — | CN | disclosed |
| EP-3755703-A1 | N-(PHENYL)-2-(PHENYL)PYRIMIDINE-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS HPK1 INHIBITORS FOR TREATING CANCER | Incyte Corporation (US) | 2020-12-30 | — | — | EP | disclosed |
| CN-112142735-A | Condensed cyanopyridine compound, preparation method and application | 上海凌达生物医药有限公司 | 2020-12-29 | — | — | CN | disclosed |
| US-20200385352-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. | 2020-12-10 | — | — | US | disclosed |
| US-20200385352-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. | 2020-12-10 | — | — | US | disclosed |
| CN-112047948-A | Kras mutant inhibitors | 山东轩竹医药科技有限公司 | 2020-12-08 | — | — | CN | disclosed |
| WO-2020243459-A1 | THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2020-12-03 | — | — | WO | disclosed |
| WO-2020239077-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海翰森生物医药科技有限公司 | 2020-12-03 | — | — | WO | disclosed |
| WO-2020239123-A1 | AROMATIC HETEROCYCLIC DERIVATIVE MODULATOR AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2020-12-03 | — | — | WO | disclosed |
| WO-2020239123-A1 | AROMATIC HETEROCYCLIC DERIVATIVE MODULATOR AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2020-12-03 | — | — | WO | disclosed |
| EP-3283462-B1 | FUSED-TRICYCLIC INHIBITORS OF KRAS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2020-12-02 | — | — | EP | disclosed |
| WO-2020227325-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1 | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2020-11-12 | — | — | WO | disclosed |
| WO-2020227325-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1 | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2020-11-12 | — | — | WO | disclosed |
| US-10829458-B2 | Substituted quinazoline compounds and methods of use thereof | ARAXES PHARMA LLC (US) | 2020-11-10 | — | — | US | disclosed |
| US-20200345732-A1 | 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2020-11-05 | — | — | US | disclosed |
| US-10822312-B2 | Substituted quinazoline compounds and methods of use | ARAXES PHARMA LLC (US) | 2020-11-03 | — | — | US | disclosed |
| US-10800761-B2 | Carboxamide compounds and uses thereof | INCYTE CORPORATION (US) | 2020-10-13 | — | — | US | disclosed |
| CN-111662232-A | Small molecule compound with 2H-indazole structure and synthesis and application thereof | 中国科学院上海药物研究所 | 2020-09-15 | — | — | CN | disclosed |
| US-20200283434-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2020-09-10 | — | — | US | disclosed |
| US-10758533-B2 | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions | NOVARTIS AG (CH) | 2020-09-01 | — | — | US | disclosed |
| US-10759756-B2 | Antagonists of human integrin α4β7 | MORPHIC THERAPEUTIC, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-10759756-B2 | Antagonists of human integrin α4β7 | MORPHIC THERAPEUTIC, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-10752635-B2 | Indazole compounds and uses thereof | INCYTE CORPORATION (US) | 2020-08-25 | — | — | US | disclosed |
| CN-107074812-B | Substituted pyrimidine compounds | 格吕伦塔尔有限公司 | 2020-08-21 | — | — | CN | disclosed |
| EP-3696174-A1 | HETEROCYCLIC MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2020-08-19 | — | — | EP | disclosed |
| US-10745388-B2 | Indazole compounds and uses thereof | INCYTE CORPORATION (US) | 2020-08-18 | — | — | US | disclosed |
| CN-106488910-B | Inhibitors of KRAS G12C | 亚瑞克西斯制药公司 | 2020-07-31 | — | — | CN | disclosed |
| US-10722495-B2 | Cyanoindazole compounds and uses thereof | INCYTE CORPORATION (US) | 2020-07-28 | — | — | US | disclosed |
| US-20200222407-A1 | COMBINATION THERAPY INCLUDING A KRAS G12C INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS | AMGEN INC. | 2020-07-16 | — | — | US | disclosed |
| US-20200222407-A1 | COMBINATION THERAPY INCLUDING A KRAS G12C INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS | AMGEN INC. | 2020-07-16 | — | — | US | disclosed |
| US-20200216446-A1 | SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. | 2020-07-09 | — | — | US | disclosed |
| US-20200216446-A1 | SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. | 2020-07-09 | — | — | US | disclosed |
| US-20200181123-A1 | 2-SUBSTITUTED QUINAZOLINE COMPOUNDS COMPRISING A SUBSTITUTED HETEROCYCLIC GROUP AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2020-06-11 | — | — | US | disclosed |
| US-20200172545-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2020-06-04 | — | — | US | disclosed |
| CN-111217843-A | Method for synthesizing 2-fluoro-6-hydroxyphenylboronic acid | 大连联化化学有限公司 | 2020-06-02 | — | — | CN | disclosed |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2020-05-28 | — | — | US | disclosed |
| WO-2020102730-A1 | IMPROVED SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. (US) | 2020-05-22 | — | — | WO | disclosed |
| WO-2020102730-A1 | IMPROVED SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. (US) | 2020-05-22 | — | — | WO | disclosed |
| US-10647675-B2 | Biaryl derivative and medicine containing same | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2020-05-12 | — | — | US | disclosed |
| US-10626111-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-04-21 | — | — | US | disclosed |
| EP-3636639-A1 | INHIBITORS OF KRAS G12C | Araxes Pharma LLC (US) | 2020-04-15 | — | — | EP | disclosed |
| CN-110997668-A | KRAS G12C inhibitors and methods of use thereof | 美国安进公司 | 2020-04-10 | — | — | CN | disclosed |
| WO-2020071778-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT EMITTING DIODE COMPRISING SAME, COMPOSITION FOR ORGANIC LAYER OF ORGANIC LIGHT EMITTING DIODE, AND METHOD FOR MANUFACTURING ORGANIC LIGHT EMITTING DIODE | 엘티소재주식회사 | 2020-04-09 | — | — | WO | disclosed |
| WO-2020070332-A1 | OXINDOLE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | ICHNOS SCIENCES S.A. (CH) | 2020-04-09 | — | — | WO | disclosed |
| WO-2020070331-A1 | INDOLINONE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | ICHNOS SCIENCES S.A. (CH) | 2020-04-09 | — | — | WO | disclosed |
| EP-3630761-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | Amgen Inc. (US) | 2020-04-08 | — | — | EP | disclosed |
| US-20200102321-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2020-04-02 | — | — | US | disclosed |
| US-20200102321-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2020-04-02 | — | — | US | disclosed |
| US-10597405-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2020-03-24 | — | — | US | disclosed |
| US-20200087301-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2020-03-19 | — | — | US | disclosed |
| US-10584126-B2 | 1-functionalized dibenzofurans and dibenzothiophenes for organic light emitting diodes (OLEDs) | IDEMITSU KOSAN CO., LTD. (JP) | 2020-03-10 | — | — | US | disclosed |
| US-20200069657-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2020-03-05 | — | — | US | disclosed |
| US-20200055845-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2020-02-20 | — | — | US | disclosed |
| US-20200048241-A1 | BENZOTHIAZOLE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2020-02-13 | — | — | US | disclosed |
| US-20200048265-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2020-02-13 | — | — | US | disclosed |
| US-10519146-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2019-12-31 | — | — | US | disclosed |
| US-20190343838-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2019-11-14 | — | — | US | disclosed |
| EP-3564233-A1 | 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | Novartis AG (CH) | 2019-11-06 | — | — | EP | disclosed |
| EP-3558955-A2 | BENZISOTHIAZOLE, ISOTHIAZOLO[3,4-B]PYRIDINE, QUINAZOLINE, PHTHALAZINE, PYRIDO[2,3-D]PYRIDAZINE AND PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS FOR TREATING LUNG, PANCREATIC OR COLORECTAL CANCER | Amgen Inc. (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20190322650-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-10-24 | — | — | US | disclosed |
| US-20190315692-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. | 2019-10-17 | — | — | US | disclosed |
| WO-2019200202-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. (US) | 2019-10-17 | — | — | WO | disclosed |
| US-20190315692-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. | 2019-10-17 | — | — | US | disclosed |
| US-20190315732-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2019-10-17 | — | — | US | disclosed |
| US-20190315717-A1 | BENZIMIDAZOLE AND INDOLE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2019-10-17 | — | — | US | disclosed |
| US-20190315743-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2019-10-17 | — | — | US | disclosed |
| WO-2019200202-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. (US) | 2019-10-17 | — | — | WO | disclosed |
| US-10435405-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2019-10-08 | — | — | US | disclosed |
| EP-3055290-B1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2019-10-02 | — | — | EP | disclosed |
| EP-3055290-B1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2019-10-02 | — | — | EP | disclosed |
| US-10428064-B2 | Fused-tricyclic inhibitors of KRAS and methods of use thereof | ARAXES PHARMA LLC (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190284144-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2019-09-19 | — | — | US | disclosed |
| US-10414757-B2 | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof | ARAXES PHARMA LLC (US) | 2019-09-17 | — | — | US | disclosed |
| WO-2019164847-A1 | INDAZOLE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION (US) | 2019-08-29 | — | — | WO | disclosed |
| WO-2019164846-A1 | N-(PHENYL)-2-(PHENYL)PYRIMIDINE-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS HPK1 INHIBITORS FOR TREATING CANCER | INCYTE CORPORATION (US) | 2019-08-29 | — | — | WO | disclosed |
| US-20190256520-A1 | INDAZOLE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2019-08-22 | — | — | US | disclosed |
| US-20190256500-A1 | INDAZOLE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2019-08-22 | — | — | US | disclosed |
| EP-3527561-A1 | NOVEL SUBSTITUTED PYRIMIDINE COMPOUNDS | Grünenthal GmbH (DE) | 2019-08-21 | — | — | EP | disclosed |
| US-10385022-B2 | 3-amino-pyridines as GPBAR1 agonists | HOFFMANN-LA ROCHE INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-10370386-B2 | Substituted quinolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2019-08-06 | — | — | US | disclosed |
| US-10370386-B2 | Substituted quinolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2019-08-06 | — | — | US | disclosed |
| EP-3510032-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER | Incyte Corporation (US) | 2019-07-17 | — | — | EP | disclosed |
| US-10351550-B2 | Substituted quinazoline compounds and methods of use thereof | ARAXES PHARMA LLC (US) | 2019-07-16 | — | — | US | disclosed |
| CN-109923114-A | Pyrazolopyridine derivatives as HPK1 modulators and their use for the treatment of cancer | 因赛特公司 | 2019-06-21 | — | — | CN | disclosed |
| US-20190177338-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2019-06-13 | — | — | US | disclosed |
| WO-2019110751-A1 | TETRACYCLIC COMPOUNDS AS INHIBITORS OF G12C MUTANT RAS PROTEIN, FOR USE AS ANTI-CANCER AGENTS | ASTRAZENECA AB (SE) | 2019-06-13 | — | — | WO | disclosed |
| EP-3492461-A1 | NITROGENOUS HETEROCYCLIC AROMATIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION THEREOF | Shanghai Yingli Pharmaceutical Co. Ltd. (CN) | 2019-06-05 | — | — | EP | disclosed |
| US-10308614-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| EP-3272754-B1 | IMIDAZOPYRROLIDINONE COMPOUNDS | NOVARTIS AG (CH) | 2019-05-29 | — | — | EP | disclosed |
| US-20190127336-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE | ARAXES PHARMA, LLC | 2019-05-02 | — | — | US | disclosed |
| US-10266530-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2019-04-23 | — | — | US | disclosed |
| US-20190106419-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2019-04-11 | — | — | US | disclosed |
| US-10246424-B2 | Substituted quinazoline compounds and methods of use thereof | ARAXES PHARMA LLC (US) | 2019-04-02 | — | — | US | disclosed |
| US-20190092767-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC | 2019-03-28 | — | — | US | disclosed |
| WO-2019051199-A1 | 6-CYANO-INDAZOLE COMPOUNDS AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS | INCYTE CORPORATION (US) | 2019-03-14 | — | — | WO | disclosed |
| US-20190076401-A1 | CYANOINDAZOLE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2019-03-14 | — | — | US | disclosed |
| US-20190055199-A1 | BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2019-02-21 | — | — | US | disclosed |
| US-10195196-B2 | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions | NOVARTIS AG (CH) | 2019-02-05 | — | — | US | disclosed |
| US-10189854-B2 | Substituted pyrimidine compounds | GRUENENTHAL GMBH (DE) | 2019-01-29 | — | — | US | disclosed |
| US-10173985-B2 | Aminoindazole derivatives as sodium channel inhibitors | ALMIRALL, S.A. (ES) | 2019-01-08 | — | — | US | disclosed |
| EP-3081553-B1 | SULFONAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF | UNIV TSUKUBA (JP) | 2018-12-12 | — | — | EP | disclosed |
| US-10144724-B2 | Substituted quinazoline compounds and methods of use thereof | ARAXES PHARMA LLC (US) | 2018-12-04 | — | — | US | disclosed |
| WO-2018217651-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2018-11-29 | — | — | WO | disclosed |
| US-20180334454-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2018-11-22 | — | — | US | disclosed |
| WO-2018049214-A9 | PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER | INCYTE CORPORATION (US) | 2018-10-18 | — | — | WO | disclosed |
| US-20180282311-A9 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-10-04 | — | — | US | disclosed |
| EP-3377481-A1 | 2-SUBSTITUTED QUINAZOLINE COMPOUNDS COMPRISING A SUBSTITUTED HETEROCYCLIC GROUP AND METHODS OF USE THEREOF | Araxes Pharma LLC (US) | 2018-09-26 | — | — | EP | disclosed |
| EP-3378863-A1 | PYRANODIPYRIDINE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2018-09-26 | — | — | EP | disclosed |
| US-20180244626-A1 | AMINOINDAZOLE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | ALMIRALL, S.A. (ES) | 2018-08-30 | — | — | US | disclosed |
| EP-3356349-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | Araxes Pharma LLC (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-3351533-A1 | BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME | Kaken Pharmaceutical Co., Ltd. (JP) | 2018-07-25 | — | — | EP | disclosed |
| US-20180194748-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2018-07-12 | — | — | US | disclosed |
| US-20180194748-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2018-07-12 | — | — | US | disclosed |
| US-10011600-B2 | Methods and compositions for inhibition of Ras | ARAXES PHARMA LLC (US) | 2018-07-03 | — | — | US | disclosed |
| US-10011600-B2 | Methods and compositions for inhibition of Ras | ARAXES PHARMA LLC (US) | 2018-07-03 | — | — | US | disclosed |
| WO-2018119183-A2 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| US-20180177767-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2018-06-28 | — | — | US | disclosed |
| EP-3325447-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND THEIR USE AS INHIBITORS OF G12C MUTANT KRAS, HRAS AND/OR NRAS PROTEINS | Araxes Pharma LLC (US) | 2018-05-30 | — | — | EP | disclosed |
| US-20180118757-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2018-05-03 | — | — | US | disclosed |
| US-20180118757-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2018-05-03 | — | — | US | disclosed |
| US-20180118757-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2018-05-03 | — | — | US | disclosed |
| US-20180105532-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180086753-A1 | FUSED-TRICYCLIC INHIBITORS OF KRAS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2018-03-29 | — | — | US | disclosed |
| US-20180086753-A1 | FUSED-TRICYCLIC INHIBITORS OF KRAS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2018-03-29 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
| WO-2018049152-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER | INCYTE CORPORATION (US) | 2018-03-15 | — | — | WO | disclosed |
| US-20180072718-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2018-03-15 | — | — | US | disclosed |
| US-20180072720-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2018-03-15 | — | — | US | disclosed |
| WO-2018049200-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER | INCYTE CORPORATION (US) | 2018-03-15 | — | — | WO | disclosed |
| WO-2018049214-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER | INCYTE CORPORATION (US) | 2018-03-15 | — | — | WO | disclosed |
| US-20180072741-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2018-03-15 | — | — | US | disclosed |
| EP-3283462-A1 | FUSED-TRICYCLIC INHIBITORS OF KRAS AND METHODS OF USE THEREOF | Araxes Pharma LLC (US) | 2018-02-21 | — | — | EP | disclosed |
| EP-3280708-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | Araxes Pharma LLC (US) | 2018-02-14 | — | — | EP | disclosed |
| EP-3274335-A1 | AMINOINDAZOLE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | Almirall S.A. (ES) | 2018-01-31 | — | — | EP | disclosed |
| EP-3272754-A1 | IMIDAZOPYRROLIDINONE COMPOUNDS | Novartis AG (CH) | 2018-01-24 | — | — | EP | disclosed |
| US-9873701-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20180009764-A1 | METHOD FOR TREATING MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS WITH IODO PYRIMIDINE DERIVATIVES | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. | 2018-01-11 | — | — | US | disclosed |
| EP-3262036-A1 | THERAPEUTIC PYRIDAZINE COMPOUNDS AND USES THEREOF | Genentech, Inc. (US) | 2018-01-03 | — | — | EP | disclosed |
| US-20170362241-A1 | 1-FUNCTIONALIZED DIBENZOFURANS AND DIBENZOTHIOPHENES FOR ORGANIC LIGHT EMITTING DIODES (OLEDS) | IDEMITSU KOSAN CO., LTD. (JP) | 2017-12-21 | — | — | US | disclosed |
| US-20170362241-A1 | 1-FUNCTIONALIZED DIBENZOFURANS AND DIBENZOTHIOPHENES FOR ORGANIC LIGHT EMITTING DIODES (OLEDS) | IDEMITSU KOSAN CO., LTD. (JP) | 2017-12-21 | — | — | US | disclosed |
| US-20170362241-A1 | 1-FUNCTIONALIZED DIBENZOFURANS AND DIBENZOTHIOPHENES FOR ORGANIC LIGHT EMITTING DIODES (OLEDS) | IDEMITSU KOSAN CO., LTD. (JP) | 2017-12-21 | — | — | US | disclosed |
| US-9840516-B2 | Substituted quinazolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2017-12-12 | — | — | US | disclosed |
| US-9840516-B2 | Substituted quinazolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2017-12-12 | — | — | US | disclosed |
| US-9840516-B2 | Substituted quinazolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2017-12-12 | — | — | US | disclosed |
| EP-2964221-B1 | COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | MERCK SHARP & DOHME (US) | 2017-12-06 | — | — | EP | disclosed |
| EP-2964221-B1 | COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | MERCK SHARP & DOHME (US) | 2017-12-06 | — | — | EP | disclosed |
| US-9815787-B2 | Sulfonamide derivative or pharmaceutically acceptable acid addition salt thereof | UNIVERSITY OF TSUKUBA (JP) | 2017-11-14 | — | — | US | disclosed |
| US-9802918-B2 | Pyridineamine compounds useful as Pim kinase inhibitors | INCYTE CORPORATION (US) | 2017-10-31 | — | — | US | disclosed |
| US-20170290828-A1 | 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | NOVARTIS AG (CH) | 2017-10-12 | — | — | US | disclosed |
| WO-2017172979-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE | ARAXES PHARMA LLC (US) | 2017-10-05 | — | — | WO | disclosed |
| US-20170247376-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF RAS | ARAXES PHARMA LLC (US) | 2017-08-31 | — | — | US | disclosed |
| US-20170247376-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF RAS | ARAXES PHARMA LLC (US) | 2017-08-31 | — | — | US | disclosed |
| US-20170247376-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF RAS | ARAXES PHARMA LLC (US) | 2017-08-31 | — | — | US | disclosed |
| EP-3208272-A1 | HETEROCYCLIC MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2017-08-23 | — | — | EP | disclosed |
| US-9738656-B2 | Pyranodipyridine compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-08-22 | — | — | US | disclosed |
| US-20170197945-A1 | 2-SUBSTITUTED QUINAZOLINE COMPOUNDS COMPRISING A SUBSTITUTED HETEROCYCLIC GROUP AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2017-07-13 | — | — | US | disclosed |
| US-20170197945-A1 | 2-SUBSTITUTED QUINAZOLINE COMPOUNDS COMPRISING A SUBSTITUTED HETEROCYCLIC GROUP AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2017-07-13 | — | — | US | disclosed |
| US-20170197945-A1 | 2-SUBSTITUTED QUINAZOLINE COMPOUNDS COMPRISING A SUBSTITUTED HETEROCYCLIC GROUP AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2017-07-13 | — | — | US | disclosed |
| US-20170158670-A1 | PYRIDINEAMINE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION | 2017-06-08 | — | — | US | disclosed |
| EP-3169681-A1 | NOVEL SUBSTITUTED PYRIMIDINE COMPOUNDS | Grünenthal GmbH (DE) | 2017-05-24 | — | — | EP | disclosed |
| US-20170137436-A1 | Pyranodipyridine Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-05-18 | — | — | US | disclosed |
| US-20170107206-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-04-20 | — | — | US | disclosed |
| US-20170107205-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-04-20 | — | — | US | disclosed |
| US-20170066776-A1 | Novel substituted pyrimidine compounds | GRUENENTHAL GMBH (DE) | 2017-03-09 | — | — | US | disclosed |
| CN-106488910-A | Inhibitors of kras g12c | 亚瑞克西斯制药公司 | 2017-03-08 | — | — | CN | disclosed |
| US-20170022184-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2017-01-26 | — | — | US | disclosed |
| US-20170022184-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2017-01-26 | — | — | US | disclosed |
| US-20170022184-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2017-01-26 | — | — | US | disclosed |
| WO-2017015562-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND THEIR USE AS INHIBITORS OF G12C MUTANT KRAS, HRAS AND/OR NRAS PROTEINS | ARAXES PHARMA LLC (US) | 2017-01-26 | — | — | WO | disclosed |
| US-9545404-B2 | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions | NOVARTIS AG (CH) | 2017-01-17 | — | — | US | disclosed |
| US-9540347-B2 | Pyridineamine compounds useful as Pim kinase inhibitors | INCYTE CORPORATION (US) | 2017-01-10 | — | — | US | disclosed |
| US-9540349-B2 | Substituted pyrimidine compounds | GRUENENTHAL GMBH (DE) | 2017-01-10 | — | — | US | disclosed |
| EP-2774925-B1 | Heterocyclic modulators of ATP-binding cassette transporters | VERTEX PHARMA (US) | 2016-12-28 | — | — | EP | disclosed |
| EP-2550257-B1 | PHARMACEUTICALLY ACTIVE DISUBSTITUTED TRIAZINE DERIVATIVES | LEAD DISCOVERY CENTER GMBH (DE) | 2016-12-21 | — | — | EP | disclosed |
| US-20160362376-A1 | SULFONAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF | UNIVERSITY OF TSUKUBA (JP) | 2016-12-15 | — | — | US | disclosed |
| WO-2016196244-A1 | PYRIDINEAMINE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION (US) | 2016-12-08 | — | — | WO | disclosed |
| US-20160347735-A1 | PYRIDINEAMINE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION | 2016-12-01 | — | — | US | disclosed |
| WO-2016168540-A1 | FUSED-TRICYCLIC INHIBITORS OF KRAS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2016-10-20 | — | — | WO | disclosed |
| WO-2016168540-A1 | FUSED-TRICYCLIC INHIBITORS OF KRAS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2016-10-20 | — | — | WO | disclosed |
| EP-3081553-A1 | SULFONAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF | University of Tsukuba (JP) | 2016-10-19 | — | — | EP | disclosed |
| US-20160297774-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2016-10-13 | — | — | US | disclosed |
| US-20160297774-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2016-10-13 | — | — | US | disclosed |
| US-20160297774-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2016-10-13 | — | — | US | disclosed |
| WO-2016164675-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2016-10-13 | — | — | WO | disclosed |
| WO-2016164675-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2016-10-13 | — | — | WO | disclosed |
| CN-106029633-A | Sulfonamide derivative or pharmaceutically acceptable acid addition salt thereof | 国立大学法人筑波大学 | 2016-10-12 | — | — | CN | disclosed |
| WO-2016150971-A1 | AMINOINDAZOLE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | ALMIRALL, S.A. (ES) | 2016-09-29 | — | — | WO | disclosed |
| US-9440952-B2 | Compounds inhibiting leucine-rich repeat kinase enzyme activity | MERCK SHARP & DOHME CORP. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9440952-B2 | Compounds inhibiting leucine-rich repeat kinase enzyme activity | MERCK SHARP & DOHME CORP. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9440952-B2 | Compounds inhibiting leucine-rich repeat kinase enzyme activity | MERCK SHARP & DOHME CORP. (US) | 2016-09-13 | — | — | US | disclosed |
| EP-3064502-A1 | IMIDAZOPYRROLIDINONE COMPOUNDS | Novartis AG (CH) | 2016-09-07 | — | — | EP | disclosed |
| WO-2016138114-A1 | THERAPEUTIC PYRIDAZINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-09-01 | — | — | WO | disclosed |
| EP-3055290-A1 | INHIBITORS OF KRAS G12C | Araxes Pharma LLC (US) | 2016-08-17 | — | — | EP | disclosed |
| EP-3045458-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen, Inc (US) | 2016-07-20 | — | — | EP | disclosed |
| US-9388189-B2 | Pyrrolotriazinone derivatives as PI3K inhibitors | ALMIRALL, S.A. (ES) | 2016-07-12 | — | — | US | disclosed |
| WO-2016097983-A1 | 1-FUNCTIONALIZED DIBENZOFURANS AND DIBENZOTHIOPHENES FOR ORGANIC LIGHT EMITTING DIODES (OLEDS) | IDEMITSU KOSAN CO., LTD. (JP) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016097983-A1 | 1-FUNCTIONALIZED DIBENZOFURANS AND DIBENZOTHIOPHENES FOR ORGANIC LIGHT EMITTING DIODES (OLEDS) | IDEMITSU KOSAN CO., LTD. (JP) | 2016-06-23 | — | — | WO | disclosed |
| EP-3034507-A1 | 1-functionalized dibenzofurans and dibenzothiophenes for organic light emitting diodes (OLEDs) | Idemitsu Kosan Co., Ltd (JP) | 2016-06-22 | — | — | EP | disclosed |
| EP-3034507-A1 | 1-functionalized dibenzofurans and dibenzothiophenes for organic light emitting diodes (OLEDs) | Idemitsu Kosan Co., Ltd (JP) | 2016-06-22 | — | — | EP | disclosed |
| US-20160143898-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-05-26 | — | — | US | disclosed |
| WO-2016049568-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF RAS | ARAXES PHARMA LLC (US) | 2016-03-31 | — | — | WO | disclosed |
| EP-2137186-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC (US) | 2016-01-27 | — | — | EP | disclosed |
| US-20160016937-A1 | Novel substituted pyrimidine compounds | GRUENENTHAL GMBH (DE) | 2016-01-21 | — | — | US | disclosed |
| WO-2016008593-A1 | NOVEL SUBSTITUTED PYRIMIDINE COMPOUNDS | Grünenthal GmbH (DE) | 2016-01-21 | — | — | WO | disclosed |
| US-20160009682-A1 | COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | MERCK SHARP & DOHME LLC | 2016-01-14 | — | — | US | disclosed |
| US-20160009682-A1 | COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | MERCK SHARP & DOHME LLC | 2016-01-14 | — | — | US | disclosed |
| US-20160009682-A1 | COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | MERCK SHARP & DOHME LLC | 2016-01-14 | — | — | US | disclosed |
| EP-2964221-A1 | COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | Merck Sharp & Dohme Corp. (US) | 2016-01-13 | — | — | EP | disclosed |
| US-20150368207-A1 | METHOD FOR TREATING MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS WITH IODO PYRIMIDINE DERIVATIVES | ADVANCED CANCER THERAPEUTICS, LLC (US) | 2015-12-24 | — | — | US | disclosed |
| US-9216969-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-12-22 | — | — | US | disclosed |
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2015-11-05 | — | — | US | disclosed |
| US-9162987-B2 | Iodo pyrimidine derivatives useful for the treatment of macrophage migration inhibitory factor (MIF)-implicated diseases and conditions | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20150291595-A1 | PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS | ALMIRALL, S.A. (ES) | 2015-10-15 | — | — | US | disclosed |
| US-9139589-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2015-08-27 | — | — | US | disclosed |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2015-08-27 | — | — | US | disclosed |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2015-08-27 | — | — | US | disclosed |
| EP-2909207-A1 | PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS | Almirall S.A. (ES) | 2015-08-26 | — | — | EP | disclosed |
| US-20150231142-A1 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | VERTEX PHARMA (US) | 2015-08-20 | — | — | US | disclosed |
| US-9090601-B2 | Thiazole derivatives | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| EP-2885288-A1 | 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | Novartis AG (CH) | 2015-06-24 | — | — | EP | disclosed |
| US-20150152058-A1 | 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS | HOFFMANN-LA ROCHE INC. | 2015-06-04 | — | — | US | disclosed |
| US-20150150879-A2 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | VERTEX PHARMACEUTICALS INCORPORATED | 2015-06-04 | — | — | US | disclosed |
| US-9024071-B2 | Therapeutic compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-9012443-B2 | Bicyclic aryl and heteroaryl sodium channel inhibitors | AMGEN INC. (US) | 2015-04-21 | — | — | US | disclosed |
| WO-2015054572-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2015-04-16 | — | — | WO | disclosed |
| WO-2015054572-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2015-04-16 | — | — | WO | disclosed |
| EP-2681194-B1 | 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS | HOFFMANN LA ROCHE (CH) | 2015-04-15 | — | — | EP | disclosed |
| US-8993600-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-03-31 | — | — | US | disclosed |
| US-8987307-B2 | 3-amino-pyridines as GPBAR1 agonists | HOFFMANN-LA ROCHE INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20150065500-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-03-05 | — | — | US | disclosed |
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-20150045361-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC (US) | 2015-02-12 | — | — | US | disclosed |
| US-20150038516-A1 | Inhibitors of Protein Kinases | ASTRAZENECA AB (SE) | 2015-02-05 | — | — | US | disclosed |
| EP-2807164-A1 | IMIDAZOPYRROLIDINONE COMPOUNDS | Novartis AG (CH) | 2014-12-03 | — | — | EP | disclosed |
| US-8901135-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20140343084-A1 | IMIDAZOPYRROLIDINONE COMPOUNDS | NOVARTIS AG (CH) | 2014-11-20 | — | — | US | disclosed |
| US-20140329814-A2 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | VERTEX PHARMA (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
| EP-2788332-A1 | BICYCLIC ARYL AND HETEROARYL SODIUM CHANNEL INHIBITORS | AMGEN, INC. (US) | 2014-10-15 | — | — | EP | disclosed |
| WO-2014137728-A1 | COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2014-09-12 | — | — | WO | disclosed |
| WO-2014137728-A1 | COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2014-09-12 | — | — | WO | disclosed |
| EP-2774925-A1 | Pharmaceutical composition containing a heterocyclic modulator of ATP-binding cassette transporters | Vertex Pharmaceuticals Incorporated (US) | 2014-09-10 | — | — | EP | disclosed |
| US-8815926-B2 | Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases | NOVARTIS AG (CH) | 2014-08-26 | — | — | US | disclosed |
| US-20140213570-A1 | 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | NOVARTIS AG (CH) | 2014-07-31 | — | — | US | disclosed |
| EP-2395002-B1 | PHARMACEUTICAL COMPOSITION CONTAINING A HETEROCYCLIC MODULATOR OF ATP-BINDING CASSETTE TRANSPORTERS. | VERTEX PHARMA (US) | 2014-06-18 | — | — | EP | disclosed |
| EP-2327692-B9 | 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-)aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors | TAKEDA PHARMACEUTICAL (JP) | 2014-06-04 | — | — | EP | disclosed |
| US-8741933-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-06-03 | — | — | US | disclosed |
| US-8729263-B2 | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions | NOVARTIS AG (CH) | 2014-05-20 | — | — | US | disclosed |
| EP-1809614-B1 | BENZOTRIAZINE INHIBITORS OF KINASES | TARGEGEN INC (US) | 2014-05-07 | — | — | EP | disclosed |
| US-8716296-B2 | Inhibitors of protein kinases | INGENIUM PHARMACEUTICALS GMBH (DE) | 2014-05-06 | — | — | US | disclosed |
| US-8716296-B2 | Inhibitors of protein kinases | INGENIUM PHARMACEUTICALS GMBH (DE) | 2014-05-06 | — | — | US | disclosed |
| US-20140121208-A1 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-05-01 | — | — | US | disclosed |
| WO-2014060432-A1 | PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS | ALMIRALL, S.A. (ES) | 2014-04-24 | — | — | WO | disclosed |
| US-20140051672-A1 | 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2014-02-20 | — | — | US | disclosed |
| WO-2014028459-A1 | 1,4-DISUBSTITUTED PYRIDAZINE ANALOGS AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | NOVARTIS AG (CH) | 2014-02-20 | — | — | WO | disclosed |
| US-20140011798-A1 | IMIDAZOPYRROLIDINONE COMPOUNDS | NOVARTIS AG (CH) | 2014-01-09 | — | — | US | disclosed |
| EP-2681194-A1 | 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-01-08 | — | — | EP | disclosed |
| US-8586739-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-8546374-B2 | Amino-tetrazoles analogues and methods of use | ABBVIE INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20130245010-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2013-09-19 | — | — | US | disclosed |
| US-20130245011-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2013-09-19 | — | — | US | disclosed |
| EP-1945632-B1 | HETEROCYCLIC MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMA (US) | 2013-09-18 | — | — | EP | disclosed |
| US-20130237568-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2013-09-12 | — | — | US | disclosed |
| US-20130237569-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2013-09-12 | — | — | US | disclosed |
| EP-2635279-A2 | CHEMICAL COMPOUNDS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2013-09-11 | — | — | EP | disclosed |
| US-20130225524-A1 | Chemical Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2013-08-29 | — | — | US | disclosed |
| EP-2628727-A2 | Biaryl PDE4 inhibitors for treating pulmonary and cardiovascular disorders | Decode Genetics EHF (IS) | 2013-08-21 | — | — | EP | disclosed |
| EP-2404919-B1 | Heterocyclic compound useful as a modulator of ATP-binding cassette transporters. | VERTEX PHARMA (US) | 2013-08-21 | — | — | EP | disclosed |
| WO-2013111105-A1 | IMIDAZOPYRROLIDINONE COMPOUNDS | NOVARTIS AG (CH) | 2013-08-01 | — | — | WO | disclosed |
| US-8481536-B2 | Benzotriazine inhibitors of kinases | TARGEGEN, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481733-B2 | Substituted imidazopyr- and imidazotri-azines | OSI Pharmaceuticals, LLC (US) | 2013-07-09 | — | — | US | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| WO-2013086229-A1 | BICYCLIC ARYL AND HETEROARYL SODIUM CHANNEL INHIBITORS | AMGEN INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| US-20130150339-A1 | Bicyclic Aryl and Heteroaryl Sodium Channel Inhibitors | AMGEN INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-8461156-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-11 | — | — | US | disclosed |
| EP-1966217-B1 | NOVEL, ACYCLIC SUBSTITUTED FUROPYRIMIDINE DERIVATIVES AND USE THEREOF FOR TREATING CARDIOVASCULAR DISEASES | BAYER IP GMBH (DE) | 2013-05-08 | — | — | EP | disclosed |
| US-8436187-B2 | 1-heterocyclylsulfonyl, 3-aminomethyl, 5- (hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| US-8415368-B2 | Acid secretion inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-04-09 | — | — | US | disclosed |
| US-20130079361-A1 | NOVEL IODO PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS | ADVANCED CANCER THERAPEUTICS, LLC | 2013-03-28 | — | — | US | disclosed |
| US-20130079345-A1 | PHARMACEUTICALLY ACTIVE DISUBSTITUTED TRIAZINE DERIVATIVES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-28 | — | — | US | disclosed |
| EP-2566868-A1 | PYRROLO [3, 2 -D]PYRIMIDIN-3 -YL DERIVATIVES USED AS ACTIVATORS OF AMPK | GlaxoSmithKline LLC (US) | 2013-03-13 | — | — | EP | disclosed |
| US-20130053407-A1 | PYRROLO [3,2-D] PYRIMIDIN-3-YL DERIVATIVES USED AS ACTIVATORS OF AMPK | GLAXOSMITHKLINE LLC (US) | 2013-02-28 | — | — | US | disclosed |
| EP-2550257-A1 | PHARMACEUTICALLY ACTIVE DISUBSTITUTED TRIAZINE DERIVATIVES | Lead Discovery Center GmbH (DE) | 2013-01-30 | — | — | EP | disclosed |
| US-8361484-B2 | Polymer systems for lung volume reduction therapy | AERIS THERAPEUTICS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| EP-2543376-A1 | Benzotriazine inhibitors of kinases | Targegen, Inc. (US) | 2013-01-09 | — | — | EP | disclosed |
| US-20120329772-A1 | AMINO-TETRAZOLES ANALOGUES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2012-12-27 | — | — | US | disclosed |
| US-8338462-B2 | 1-heterocyclylsulfonyl, 3-aminomethyl, 5- (hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors | TAKEDA PHARMACEUTICALS COMPANY LIMITED (JP) | 2012-12-25 | — | — | US | disclosed |
| US-8338461-B2 | 1-heterocyclylsulfonyl, 3-aminomethyl, 5-(hetero-)aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-25 | — | — | US | disclosed |
| US-20120322798-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-12-20 | — | — | US | disclosed |
| EP-2039683-B1 | Vasculostatic agents and methods of use thereof | TARGEGEN INC (US) | 2012-12-19 | — | — | EP | disclosed |
| US-8324207-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-12-04 | — | — | US | disclosed |
| US-8318733-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-27 | — | — | US | disclosed |
| US-20120289502-A1 | IMIDAZOLE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-11-15 | — | — | US | disclosed |
| EP-2283020-B1 | SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES | OSI PHARM INC (US) | 2012-10-31 | — | — | EP | disclosed |
| US-8299261-B2 | 1-heterocyclylsulfonyl, 3-aminomethyl, 5-(hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-30 | — | — | US | disclosed |
| US-8273738-B2 | Imidazole derivatives | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-09-25 | — | — | US | disclosed |
| US-20120232059-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-13 | — | — | US | disclosed |
| US-20120232051-A1 | 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS | HOFFMANN-LA ROCHE INC. | 2012-09-13 | — | — | US | disclosed |
| WO-2012117000-A1 | 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-07 | — | — | WO | disclosed |
| US-20120220585-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-20120220586-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-20120213758-A1 | BIARYL PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | DeCODE Genetics enf (IS) | 2012-08-23 | — | — | US | disclosed |
| US-20120213758-A1 | BIARYL PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | DeCODE Genetics enf (IS) | 2012-08-23 | — | — | US | disclosed |
| EP-1966158-B1 | SUBSTITUTED CINNOLINE DERIVATIVES AS GABAA-RECEPTOR MODULATORS AND METHOD FOR THEIR SYNTHESIS | ASTRAZENECA AB (SE) | 2012-08-08 | — | — | EP | disclosed |
| EP-2480235-A2 | NOVEL IODO PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS | University Of Louisville Research Foundation, Inc. (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-2475660-A1 | PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK | GlaxoSmithKline LLC (US) | 2012-07-18 | — | — | EP | disclosed |
| EP-2327692-B1 | 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-)aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors | TAKEDA PHARMACEUTICAL (JP) | 2012-07-18 | — | — | EP | disclosed |
| US-8217067-B2 | Antiinflammatory agents, antidepressants, analgesics, purinergic receptor antagonists; neurodegenerative diseases, spinal cord injuries; 1-(2,3-dichlorophenyl)-N-[(2-methylphenyl)methyl]-1H-tetraazol-5-amine | ABBOTT LABORATORIES (US) | 2012-07-10 | — | — | US | disclosed |
| US-20120172333-A1 | PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK | GLAXOSMITHKLINE LLC (US) | 2012-07-05 | — | — | US | disclosed |
| US-8193199-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8183246-B2 | Acyclically substituted furopyrimidine derivatives and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-05-22 | — | — | US | disclosed |
| WO-2012061557-A2 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2012-05-10 | — | — | WO | disclosed |
| US-20120088797-A1 | 1-HETEROCYCLYLSULFONYL, 3-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-12 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2404919-A1 | Pharmaceutical composition containing a heterocyclic modulator of ATP-binding cassette transporters. | Vertex Pharmaceuticals Incorporated (US) | 2012-01-11 | — | — | EP | disclosed |
| US-20110312958-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-12-22 | — | — | US | disclosed |
| EP-2395002-A1 | Pharmaceutical composition containing a heterocyclic modulator of ATP-binding cassette transporters. | Vertex Pharmaceuticals Incorporated (US) | 2011-12-14 | — | — | EP | disclosed |
| US-20110301174-A1 | 1-HETEROCYCLYLSULFONYL, 3-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-08 | — | — | US | disclosed |
| US-20110301173-A1 | 1-HETEROCYCLYLSULFONYL, 3-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-08 | — | — | US | disclosed |
| EP-2391619-A1 | HETEROARYLS AND THEIR USE AS PI3K INHIBITORS | Millennium Pharmaceuticals, Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
| US-20110294796-A1 | BENZOTRIAZINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| WO-2011138307-A1 | PYRROLO [3, 2 -D] PYRIMIDIN-3 -YL DERIVATIVES USED AS ACTIVATORS OF AMPK | GLAXOSMITHKLINE LLC (US) | 2011-11-10 | — | — | WO | disclosed |
| EP-2090570-B1 | IMIDAZOLE DERIVATIVE | KYOWA HAKKO KIRIN CO LTD (JP) | 2011-11-09 | — | — | EP | disclosed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| US-8030339-B2 | Imidazole derivatives for the treatment of anxiety and related diseases | NEUROSEARCH A/S (DK) | 2011-10-04 | — | — | US | disclosed |
| WO-2011116951-A1 | PHARMACEUTICALLY ACTIVE DISUBSTITUTED TRIAZINE DERIVATIVES | LEAD DISCOVERY CENTER GMBH (DE) | 2011-09-29 | — | — | WO | disclosed |
| US-20110172229-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-14 | — | — | US | disclosed |
| US-7977488-B2 | 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-12 | — | — | US | disclosed |
| US-7973038-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-05 | — | — | US | disclosed |
| US-20110144161-A1 | 1-HETEROCYCLYLSULFONYL, 2-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-16 | — | — | US | disclosed |
| US-20110144331-A1 | Cinnoline Compounds for the Treatment of Anxiety, Cognitive and Mood Disorders | ASTRAZENECA AB (SE) | 2011-06-16 | — | — | US | disclosed |
| US-20110144331-A1 | Cinnoline Compounds for the Treatment of Anxiety, Cognitive and Mood Disorders | ASTRAZENECA AB (SE) | 2011-06-16 | — | — | US | disclosed |
| US-20110144331-A1 | Cinnoline Compounds for the Treatment of Anxiety, Cognitive and Mood Disorders | ASTRAZENECA AB (SE) | 2011-06-16 | — | — | US | disclosed |
| US-7956052-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-07 | — | — | US | disclosed |
| EP-2327692-A1 | 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-)aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2011-06-01 | — | — | EP | disclosed |
| EP-2212297-B1 | INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2011-05-25 | — | — | EP | disclosed |
| US-7939556-B2 | Imidazole derivatives and their use for modulating the GABAA receptor complex | NEUROSEARCH A/S (DK) | 2011-05-10 | — | — | US | disclosed |
| US-20110098311-A1 | COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES | Vertex Pharmaceuticals Incorported (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110092553-A1 | Substituted Azole Derivatives, Compositions, and Methods of Use | TRANSTECH PHARMA, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| EP-1919865-B1 | 1-HETEROCYCLYLSULFONYL, 2-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2011-04-06 | — | — | EP | disclosed |
| US-20110077399-A1 | Substituted Azole Derivatives as Therapeutic Agents | TRANSTECH PHARMA, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| WO-2011038234-A2 | NOVEL IODO PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2011-03-31 | — | — | WO | disclosed |
| WO-2011029855-A1 | PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK | GLAXOSMITHKLINE LLC (US) | 2011-03-17 | — | — | WO | disclosed |
| EP-2283020-A1 | SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES | OSI Pharmaceuticals, Inc. (US) | 2011-02-16 | — | — | EP | disclosed |
| US-20110003807-A1 | Thiazole derivatives | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110003806-A1 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20100330030-A1 | Vasculostatic Agents and Methods of Use Thereof | TARGEGEN, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100286152-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | GLAXO GROUP LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| US-20100278811-A1 | VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF | TARGEGEN INC. | 2010-11-04 | — | — | US | disclosed |
| WO-2010123441-A1 | CRYSTALLINE FORM OF 4-AMINO-8-(2-FLUORO-6-METHOXY-PHENYL)-N-PROPYLCINNOLINE-3- CARBOXAMIDE HYDROGEN SULPHATE, FOR TREATMENT OF ANXIETY DISORDERS | ASTRAZENECA AB (SE) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010123441-A1 | CRYSTALLINE FORM OF 4-AMINO-8-(2-FLUORO-6-METHOXY-PHENYL)-N-PROPYLCINNOLINE-3- CARBOXAMIDE HYDROGEN SULPHATE, FOR TREATMENT OF ANXIETY DISORDERS | ASTRAZENECA AB (SE) | 2010-10-28 | — | — | WO | disclosed |
| US-20100249149-A1 | Inhibitors of Protein Kinases | ASTRAZENECA AB (SE) | 2010-09-30 | — | — | US | disclosed |
| US-20100249149-A1 | Inhibitors of Protein Kinases | ASTRAZENECA AB (SE) | 2010-09-30 | — | — | US | disclosed |
| US-20100210638-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-19 | — | — | US | disclosed |
| WO-2010090716-A1 | HETEROARYLS AND THEIR USE AS PI3K INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
| EP-2212297-A1 | INHIBITORS OF PROTEIN KINASES | Ingenium Pharmaceuticals GmbH (DE) | 2010-08-04 | — | — | EP | disclosed |
| US-20100184738-A1 | Uses of cinnoline compounds to treat schizophrenia | ASTRAZENECA AB (SE) | 2010-07-22 | — | — | US | disclosed |
| US-20100184738-A1 | Uses of cinnoline compounds to treat schizophrenia | ASTRAZENECA AB (SE) | 2010-07-22 | — | — | US | disclosed |
| US-20100184738-A1 | Uses of cinnoline compounds to treat schizophrenia | ASTRAZENECA AB (SE) | 2010-07-22 | — | — | US | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
| US-7741321-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-22 | — | — | US | disclosed |
| US-20100152178-A1 | IMIDAZOLE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-06-17 | — | — | US | disclosed |
| US-7723367-B2 | Amino-tetrazoles analogues and methods of use | ABBOTT LABORATORIES (US) | 2010-05-25 | — | — | US | disclosed |
| US-7704997-B1 | Amino-tetrazole analogues and methods of use | ABBOTT LABORATORIES (US) | 2010-04-27 | — | — | US | disclosed |
| EP-2176263-A2 | FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS | AstraZeneca AB (SE) | 2010-04-21 | — | — | EP | disclosed |
| US-20100087435-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-08 | — | — | US | disclosed |
| EP-2167091-A1 | CINNOLINE COMPOUNDS FOR USE IN THE TREATMENT OF SCHIZOPHRENIA | AstraZeneca AB (SE) | 2010-03-31 | — | — | EP | disclosed |
| EP-2167466-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | Glaxo Group Limited (GB) | 2010-03-31 | — | — | EP | disclosed |
| US-20100040538-A1 | Polymer Systems for Lung Volume Reduction Therapy | CANADIAN IMPERIAL BANK OF COMMERCE (CA) | 2010-02-18 | — | — | US | disclosed |
| US-7659268-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-02-09 | — | — | US | disclosed |
| US-7645773-B2 | Thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenase | HOFFMANN-LA ROCHE INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-7645773-B2 | Thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenase | HOFFMANN-LA ROCHE INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-7645773-B2 | Thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenase | HOFFMANN-LA ROCHE INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-7642361-B2 | Thiophene and furan compounds | ELI LILLY AND COMPANY (US) | 2010-01-05 | — | — | US | disclosed |
| US-7642361-B2 | Thiophene and furan compounds | ELI LILLY AND COMPANY (US) | 2010-01-05 | — | — | US | disclosed |
| EP-2137186-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen Inc. (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20090318475-A1 | Novel, Acyclically Substituted Furopyrimidine Derivatives and Use Thereof | BAYER HEALTHCARE AG (DE) | 2009-12-24 | — | — | US | disclosed |
| WO-2009143051-A1 | SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES | OSI PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| US-20090286768-A1 | SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES | OSI PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090275591-A1 | 1-HETEROCYCLYLSULFONYL, 2-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2009-11-05 | — | — | US | disclosed |
| US-20090275569-A1 | Benzotriazine Inhibitors of Kinases | TARGEGEN, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090233929-A1 | Imidazole Derivatives for the Treatment of Anxiety and Related Diseases | NEUROSEARCH A/S (DK) | 2009-09-17 | — | — | US | disclosed |
| US-20090215777-A1 | Pyrimidine Derivatives As HSP90 Inhibitors | ASTEX THERAPEUTICS LTD. (GB) | 2009-08-27 | — | — | US | disclosed |
| US-20090215778-A1 | Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives | PANACOS PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090209597-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA ALPHA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2009-08-20 | — | — | US | disclosed |
| EP-2090570-A1 | IMIDAZOLE DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2009-08-19 | — | — | EP | disclosed |
| US-20090143444-A1 | ACID SECRETION INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-04 | — | — | US | disclosed |
| US-20090137581-A1 | Heterocyclic compounds and their uses | AMGEN INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090136473-A1 | BIARYL PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | DECODE GENETICS EHF (IS) | 2009-05-28 | — | — | US | disclosed |
| US-20090136473-A1 | BIARYL PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | DECODE GENETICS EHF (IS) | 2009-05-28 | — | — | US | disclosed |
| WO-2009067621-A1 | BIARYL PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | DECODE GENETICS EHF (IS) | 2009-05-28 | — | — | WO | disclosed |
| EP-2059227-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | Aeris Therapeutics, Inc. (US) | 2009-05-20 | — | — | EP | disclosed |
| US-20090105477-A1 | Quinazoline Protein Tyrosine Phosphatase Inhibitors | BERTHEL STEVEN JOSEPH | 2009-04-23 | — | — | US | disclosed |
| WO-2009047359-A1 | INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2009-04-16 | — | — | WO | disclosed |
| EP-2039683-A2 | Vasculostatic agents and methods of use thereof | Targegen, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| US-7498337-B2 | Acid secretion inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-03 | — | — | US | disclosed |
| US-20090036454-A1 | Compounds and Uses Thereof | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | US | disclosed |
| US-20090036454-A1 | Compounds and Uses Thereof | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | US | disclosed |
| US-20090018112-A1 | Compounds and Uses Thereof | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | US | disclosed |
| US-20090018112-A1 | Compounds and Uses Thereof | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | US | disclosed |
| US-20080318925-A1 | Compounds and Uses Thereof - 849 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| US-20080318925-A1 | Compounds and Uses Thereof - 849 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| US-20080318925-A1 | Compounds and Uses Thereof - 849 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| WO-2008155572-A2 | FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS | ASTRAZENECA AB (SE) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008155573-A1 | CINNOLINE COMPOUNDS FOR USE IN THE TREATMENT OF SCHIZOPHRENIA | ASTRAZENECA AB (SE) | 2008-12-24 | — | — | WO | disclosed |
| US-7465795-B2 | Compounds and uses thereof | ASTRAZENECA AB (SE) | 2008-12-16 | — | — | US | disclosed |
| US-7465795-B2 | Compounds and uses thereof | ASTRAZENECA AB (SE) | 2008-12-16 | — | — | US | disclosed |
| WO-2008148853-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | GLAXO GROUP LIMITED (GB) | 2008-12-11 | — | — | WO | disclosed |
| US-20080306062-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2008-12-11 | — | — | US | disclosed |
| US-7456176-B2 | Benzotriazine inhibitors of kinases | TARGEGEN, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| WO-2008134036-A1 | ALPHA-SUBSTITUTED ARYLMETHYL PIPERAZINE PYRAZOLO[1,5-α]PYRIMIDINE AMIDE DERIVATIVES | PANACOS PHARMACEUTICALS, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008131858-A2 | USE OF ACYCLICALLY SUBSTITUTED FUROPYRIMIDINE DERIVATIVES FOR TREATING PULMONARY ARTERIAL HYPERTONIA | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-11-06 | — | — | WO | disclosed |
| EP-1979335-A2 | THIAZOLES AS 11 BETA-HSD1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-15 | — | — | EP | disclosed |
| WO-2008118468-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2008-10-02 | — | — | WO | disclosed |
| US-7425556-B2 | Compounds and uses thereof | ASTRAZENECA AB (SE) | 2008-09-16 | — | — | US | disclosed |
| US-7425556-B2 | Compounds and uses thereof | ASTRAZENECA AB (SE) | 2008-09-16 | — | — | US | disclosed |
| EP-1966158-A1 | SUBSTITUTED CINNOLINE DERIVATIVES AS GABAA-RECEPTOR MODULATORS AND METHOD FOR THEIR SYNTHESIS | AstraZeneca AB (SE) | 2008-09-10 | — | — | EP | disclosed |
| EP-1966217-A1 | NOVEL, ACYCLIC SUBSTITUTED FUROPYRIMIDINE DERIVATIVES AND USE THEREOF FOR TREATING CARDIOVASCULAR DISEASES | Bayer HealthCare AG (DE) | 2008-09-10 | — | — | EP | disclosed |
| US-20080182891-A1 | CHROMANE AND CHROMENE DERIVATIVES AND USES THEREOF | WYETH (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080171733-A1 | Amino-Tetrazoles Analogues and Methods of Use | ABBOTT LABORATORIES (US) | 2008-07-17 | — | — | US | disclosed |
| EP-1940822-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA-A RECEPTOR COMPLEX | NeuroSearch A/S (DK) | 2008-07-09 | — | — | EP | disclosed |
| CN-101218223-A | Benzodioxane and benzodioxolane derivatives and uses thereof | WYETH CORP (US) | 2008-07-09 | — | — | CN | disclosed |
| EP-1937649-A1 | IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF ANXIETY AND RELATED DISEASES | NEUROSEARCH A/S (DK) | 2008-07-02 | — | — | EP | disclosed |
| CN-101203505-A | Chromane and chromene derivatives and uses thereof | WYETH CORP (US) | 2008-06-18 | — | — | CN | disclosed |
| WO-2008061006-A1 | SUBSTITUTED INDAN-2-YL, TETRAHYDRONAPHTHALEN-2-YL, OR DIHYDR0-2H-CHR0MEN-3-YL ARYLSULFONAMIDES AND METHODS OF THEIR USE | WYETH (US) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008061016-A1 | N-SUBSTITUTED PIPERIDINYL 4 -ARYLSULFONAMIDES AS MODULATORS OF THE SECRETED FRIZZLED RELATED PROTEIN- 1 | WYETH (US) | 2008-05-22 | — | — | WO | disclosed |
| US-20080113985-A1 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2008-05-15 | — | — | US | disclosed |
| US-7365095-B2 | Chromane and chromene derivatives and uses thereof | WYETH (US) | 2008-04-29 | — | — | US | disclosed |
| EP-1549614-A4 | VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF | TARGEGEN INC (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2008039827-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | AERIS THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | disclosed |
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-24 | — | — | US | disclosed |
| EP-1874756-A1 | CHROMANE AND CHROMENE DERIVATIVES AND USES THEREOF | Wyeth (US) | 2008-01-09 | — | — | EP | disclosed |
| EP-1871759-A1 | BENZODIOXANE AND BENZODIOXOLANE DERIVATIVES AND USES THEREOF | Wyeth a Corporation of the State of Delaware (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20070208019-A1 | Vasculostatic agents and methods of use thereof | TARGEGEN, INC. | 2007-09-06 | — | — | US | disclosed |
| EP-1812409-A1 | AMINOQUINAZOLINES COMPOUNDS | F. Hoffmann-Roche AG (CH) | 2007-08-01 | — | — | EP | disclosed |
| WO-2007082808-A2 | THIAZOLES AS 11 BETA-HSD1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007082808-A2 | THIAZOLES AS 11 BETA-HSD1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-07-26 | — | — | WO | disclosed |
| EP-1809614-A2 | BENZOTRIAZINE INHIBITORS OF KINASES | Targegen, Inc. (US) | 2007-07-25 | — | — | EP | disclosed |
| WO-2007079862-A1 | NOVEL, ACYCLIC SUBSTITUTED FUROPYRIMIDINE DERIVATIVES AND USE THEREOF FOR TREATING CARDIOVASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2007-07-19 | — | — | WO | disclosed |
| US-20070167622-A1 | [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome | GILLESPIE PAUL | 2007-07-19 | — | — | US | disclosed |
| US-20070167622-A1 | [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome | GILLESPIE PAUL | 2007-07-19 | — | — | US | disclosed |
| US-20070167622-A1 | [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome | GILLESPIE PAUL | 2007-07-19 | — | — | US | disclosed |
| WO-2007073283-A1 | SUBSTITUTED CINNOLINE DERIVATIVES AS GABAA-RECEPTOR MODULATORS AND METHOD FOR THEIR SYNTHESIS | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
| US-20070142328-A1 | Compounds and Uses Thereof | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | US | disclosed |
| US-20070142328-A1 | Compounds and Uses Thereof | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | US | disclosed |
| US-20070142382-A1 | Compounds and Uses Thereof | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | US | disclosed |
| US-20070142382-A1 | Compounds and Uses Thereof | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | US | disclosed |
| US-20070105852-A1 | Thiophene and furan compounds | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| US-20070105852-A1 | Thiophene and furan compounds | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| US-7208493-B2 | Vasculostatic agents and methods of use thereof | TARGEGEN, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| WO-2007042545-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA-A RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007042546-A1 | IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF ANXIETY AND RELATED DISEASES | NEUROSEARCH A/S (DK) | 2007-04-19 | — | — | WO | disclosed |
| US-20070060623-A1 | antiulcer agents; proton pump inhibitors; side effect reduction; 1-[4-fluoro-5-phenyl-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine; superior acid secretion inhibitory effect; peptic ulcer, Zollinger-Ellison syndrome, reflux esophagitis, or symptomatic gastroesophageal reflux disease | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-15 | — | — | US | disclosed |
| US-20070049584-A1 | Amino-tetrazoles analogues and methods of use | ABBVIE INC. | 2007-03-01 | — | — | US | disclosed |
| EP-1747206-A1 | AMINO-TETRAZOLES ANALOGUES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2007-01-31 | — | — | EP | disclosed |
| US-20060287356-A1 | dietetics or antidiabetic agents such as 4-hydroxy-3-(4'-hydroxy-1,1'-biphenyl-4-yl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-5-carbonitrile, used for prophylaxis of metabolic disorders | IYENGAR RAJESH R | 2006-12-21 | — | — | US | disclosed |
| US-7151098-B2 | Glutamate receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2006-12-19 | — | — | US | disclosed |
| EP-1730118-A1 | SUBSTITUTED AZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | Transtech Pharma, Inc. (US) | 2006-12-13 | — | — | EP | disclosed |
| US-20060258714-A1 | Chromane and chromene derivatives and uses thereof | WYETH (US) | 2006-11-16 | — | — | US | disclosed |
| WO-2006116165-A1 | CHROMANE AND CHROMENE DERIVATIVES AND USES THEREOF | WYETH (US) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006116158-A1 | BENZODIOXANE AND BENZODIOXOLANE DERIVATIVES AND USES THEREOF | WYETH (US) | 2006-11-02 | — | — | WO | disclosed |
| US-20060241172-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | WYETH (US) | 2006-10-26 | — | — | US | disclosed |
| US-7119205-B2 | Thienopyridones as AMPK activators for the treatment of diabetes and obesity | ABBOTT LABORATORIES (US) | 2006-10-10 | — | — | US | disclosed |
| US-20060211715-A1 | Quinazoline protein tyrosine phosphatase inhibitors | BERTHEL STEVEN J | 2006-09-21 | — | — | US | disclosed |
| US-20060148791-A1 | Glutamate receptor antagonists | ADAM GEO | 2006-07-06 | — | — | US | disclosed |
| WO-2006051410-A1 | AZABENZOXAZOLES FOR THE TREATMENT OF CNS DISORDERS | PFIZER INC. (US) | 2006-05-18 | — | — | WO | disclosed |
| WO-2006050843-A1 | AMINOQUINAZOLINES COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-18 | — | — | WO | disclosed |
| US-7018998-B2 | Glutamate receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2006-03-28 | — | — | US | disclosed |
| US-20060052374-A1 | Amino-tetrazole analogues and methods of use | ABBVIE INC. | 2006-03-09 | — | — | US | disclosed |
| US-20050282814-A1 | Vasculostatic agents and methods of use thereof | TARGEGEN, INC. (US) | 2005-12-22 | — | — | US | disclosed |
| WO-2005111003-A1 | AMINO-TETRAZOLES ANALOGUES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2005-11-24 | — | — | WO | disclosed |
| EP-1594847-A2 | SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | Transtech Pharma, Inc. (US) | 2005-11-16 | — | — | EP | disclosed |
| US-20050245524-A1 | Benzotriazine inhibitors of kinases | TARGEGEN, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| US-6960578-B2 | Glutamate receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2005-11-01 | — | — | US | disclosed |
| US-20050234048-A1 | Glutamate receptor antagonists | ADAM GEO | 2005-10-20 | — | — | US | disclosed |
| WO-2005096784-A2 | BENZOTRIAZINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| WO-2004071447-A9 | SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | TRANSTECH PHARMA INC (US) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005080346-A1 | SUBSTITUTED AZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| US-20050187277-A1 | Substituted azole derivatives, compositions, and methods of use | TRANSTECH PHARMA, INC. | 2005-08-25 | — | — | US | disclosed |
| WO-2005070916-A1 | THIOPHENE AND FURAN COMPOUNDS | ELI LILLY AND COMPANY (US) | 2005-08-04 | — | — | WO | disclosed |
| EP-1549614-A2 | VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF | Targegen, Inc. (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20050038068-A1 | Thienopyridones as AMPK activators for the treatment of diabetes and obesity | ABBVIE INC. | 2005-02-17 | — | — | US | disclosed |
| US-20040242633-A1 | Beta3 adrenergic agonists | EVERS BRITTA (DE) | 2004-12-02 | — | — | US | disclosed |
| US-20040192743-A1 | Substituted azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. | 2004-09-30 | — | — | US | disclosed |
| WO-2004071447-A2 | SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | TRANSTECH PHARMA INC. (US) | 2004-08-26 | — | — | WO | disclosed |
| US-20040167198-A1 | Vasculostatic agents and methods of use thereof | TARGEGEN, INC. | 2004-08-26 | — | — | US | disclosed |
| US-6730792-B2 | PYRIDINE DERIVATIVES; ANTIDIABETIC, ANTICHOLESTEROL, AND ANTIINFLAMMATORY AGENTS; DECYCLIZATION, DEETHERIFICATION; OBESITY; RAISES HIGH DENSITY LIPOPROTEINS; LOWERS TRIGLYCERIDE LEVELS | ELI LILLY AND COMPANY | 2004-05-04 | — | — | US | disclosed |
| WO-2004030635-A2 | VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF | TARGEGEN, INC. (US) | 2004-04-15 | — | — | WO | disclosed |
| EP-1224175-B1 | BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2004-03-17 | — | — | EP | disclosed |
| US-20030191156-A1 | Beta3 adrenergic agonists | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2003-10-09 | — | — | US | disclosed |
| US-20030092677-A1 | Glutamate receptor antagonists | ADAM GEO (DE) | 2003-05-15 | — | — | US | disclosed |
| EP-1303509-A1 | BETA3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 2003-04-23 | — | — | EP | disclosed |
| US-6509328-B1 | Metabotropic glutamate receptor antagonists and accordingly are useful for the treatment of a range of neurological disorders, including psychosis, schizophrenia, Alzheimer's and others | HOFFMANN-LA ROCHE INC. | 2003-01-21 | — | — | US | disclosed |
| EP-1224175-A2 | BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-24 | — | — | EP | disclosed |
| WO-2002006276-A1 | BETA3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 2002-01-24 | — | — | WO | disclosed |
| WO-2001029012-A2 | BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-26 | — | — | WO | disclosed |
| WO-2001029012-A2 | BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249149-A1 | Inhibitors of Protein Kinases | CDK9, CDK19, CDK2 | ENPP2 2597/4885ORAI1 4630/4885ORAI2 3730/4885 |
| US-20170247376-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF RAS | KRAS, NRAS, HRAS | ENPP2 2623/4885ORAI1 4468/4885ORAI2 4237/4885 |
| US-12384778-B2 | Pyrazolopyridine compounds and uses thereof | PDXK, PCK1, PGK1 | ENPP2 1420/4885ORAI1 4493/4885ORAI2 4630/4885 |
| US-10385022-B2 | 3-amino-pyridines as GPBAR1 agonists | GPBAR1, ADRA1B, GPR119 | ENPP2 880/4885ORAI1 1378/4885ORAI2 1840/4885 |
| US-20200048265-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | ENPP2 113/4885ORAI1 2374/4885ORAI2 1873/4885 |
| US-20040192743-A1 | Substituted azole derivatives as therapeutic agents | PTPRS, PTPRO, PTPRJ | ENPP2 216/4885ORAI1 4787/4885ORAI2 4548/4885 |
| US-20240383889-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PGK1 | ENPP2 1420/4885ORAI1 4493/4885ORAI2 4630/4885 |
| US-20110092553-A1 | Substituted Azole Derivatives, Compositions, and Methods of Use | PTPRO, PTPN5, PTPRE | ENPP2 402/4885ORAI1 4769/4885ORAI2 4613/4885 |
| US-20250163032-A1 | NOVEL MOLECULES AS INHIBITORS OF DNA DAMAGE REPAIR PATHWAY | ERCC2, DDB1, UNG | ENPP2 2411/4885ORAI1 4764/4885ORAI2 4713/4885 |
| US-12630547-B2 | RAS protein degraders, pharmaceutical compositions thereof, and their therapeutic applications | KRAS, RSU1, NRAS | ENPP2 1978/4885ORAI1 4486/4885ORAI2 4318/4885 |
| US-10800761-B2 | Carboxamide compounds and uses thereof | PCK1, PHKG2, PHKG1 | ENPP2 824/4885ORAI1 4692/4885ORAI2 4802/4885 |
| US-10758533-B2 | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions | SMN1; SMN2, CLN6, SF3B5 | ENPP2 1200/4885ORAI1 4273/4885ORAI2 4387/4885 |
| US-20250179068-A1 | SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | KRAS, NRAS, HRAS | ENPP2 1573/4885ORAI1 4098/4885ORAI2 3362/4885 |
| US-11299473-B2 | Benzimidazole and indole compounds and uses thereof | PGK1, PDXK, HIPK1 | ENPP2 2764/4885ORAI1 4803/4885ORAI2 4563/4885 |
| US-10745388-B2 | Indazole compounds and uses thereof | PDXK, PPIP5K2, PCK1 | ENPP2 1875/4885ORAI1 4844/4885ORAI2 4708/4885 |
| US-12247021-B2 | Substituted tetrahydrofurans as modulators of sodium channels | TRPV1, TRPA1, SCN2B | ENPP2 2199/4885ORAI1 117/4885ORAI2 201/4885 |
| US-20230286961-A1 | SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | TRPV1, TRPA1, SCN2B | ENPP2 2199/4885ORAI1 117/4885ORAI2 201/4885 |
| US-20260049074-A1 | THIADIAZOLYL DERIVATIVES | POLH, POLM, POLD1 | ENPP2 3365/4885ORAI1 4637/4885ORAI2 4608/4885 |
| US-20030092677-A1 | Glutamate receptor antagonists | GRM1, GRM3, GRM2 | ENPP2 858/4885ORAI1 1544/4885ORAI2 1310/4885 |
| US-20100087435-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | ENPP2 468/4885ORAI1 1787/4885ORAI2 735/4885 |
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C9, SSB, C1S | ENPP2 591/4885ORAI1 3052/4885ORAI2 4630/4885 |
| US-20090143444-A1 | ACID SECRETION INHIBITOR | HRH2, VIP, CCKBR | ENPP2 653/4885ORAI1 414/4885ORAI2 2678/4885 |
| US-20220213100-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | KRAS, NRAS, GNAQ | ENPP2 3065/4885ORAI1 4122/4885ORAI2 4762/4885 |
| US-20120232051-A1 | 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS | GPBAR1, ADRA1B, GPR119 | ENPP2 880/4885ORAI1 1378/4885ORAI2 1840/4885 |
| US-20110301174-A1 | 1-HETEROCYCLYLSULFONYL, 3-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITORS | CMA1, GIPR, CTRL | ENPP2 1136/4885ORAI1 1360/4885ORAI2 3470/4885 |
| US-20140011798-A1 | IMIDAZOPYRROLIDINONE COMPOUNDS | MDM4, MDM2, TP53 | ENPP2 2960/4885ORAI1 4608/4885ORAI2 4208/4885 |
| US-20220267322-A1 | OXAZOLE COMPOUND AS MULTI-TARGETED INHIBITOR OF IRAK4 AND BTK | IRAK4, IRAK2, IRAK3 | ENPP2 2552/4885ORAI1 2303/4885ORAI2 1042/4885 |
| US-20090215778-A1 | Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives | THPO, DPYD, TPMT | ENPP2 3071/4885ORAI1 4268/4885ORAI2 3563/4885 |
| US-12441727-B2 | Tricyclic compounds as inhibitors of KRAS | KRAS, NRAS, HRAS | ENPP2 2518/4885ORAI1 4502/4885ORAI2 4343/4885 |
| US-20240174660-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | ENPP2 698/4885ORAI1 4675/4885ORAI2 3377/4885 |
| US-20240262828-A1 | Functionalized Heterocycles as Antiviral Agents | HCCS, HAVCR2, HDGF | ENPP2 3296/4885ORAI1 3981/4885ORAI2 2761/4885 |
| US-20230399327-A1 | HIGH ACTIVITY HPK1 KINASE INHIBITOR | MAP3K9, MAP3K1, MAP3K15 | ENPP2 786/4885ORAI1 4632/4885ORAI2 4611/4885 |
| US-20240016058-A1 | NOVEL ORGANIC COMPOUND, AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | CYBA, AOX1, CYP1B1 | ENPP2 2988/4885ORAI1 1480/4885ORAI2 41/4885 |
| US-20190177338-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, MCL1 | ENPP2 2990/4885ORAI1 4374/4885ORAI2 4543/4885 |
| US-20200172545-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, MAPKAPK5 | ENPP2 1585/4885ORAI1 4776/4885ORAI2 4806/4885 |
| US-20210188869-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | ENPP2 1962/4885ORAI1 3303/4885ORAI2 4691/4885 |
| US-10722495-B2 | Cyanoindazole compounds and uses thereof | PCK1, PDXK, PHKG1 | ENPP2 2144/4885ORAI1 4840/4885ORAI2 4829/4885 |
| US-20230056631-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | ENPP2 2349/4885ORAI1 4439/4885ORAI2 4367/4885 |
| US-20190315717-A1 | BENZIMIDAZOLE AND INDOLE COMPOUNDS AND USES THEREOF | PGK1, PDXK, HIPK1 | ENPP2 2764/4885ORAI1 4803/4885ORAI2 4563/4885 |
| US-11897891-B2 | Tricyclic heterocycles as FGFR inhibitors | FGFR3, FGFR1, FGFR2 | ENPP2 3169/4885ORAI1 4824/4885ORAI2 4755/4885 |
| US-20110294796-A1 | BENZOTRIAZINE INHIBITORS OF KINASES | SRC, CAMK4, CAMK2G | ENPP2 1856/4885ORAI1 158/4885ORAI2 75/4885 |
| US-20200087301-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PGK1 | ENPP2 1420/4885ORAI1 4493/4885ORAI2 4630/4885 |
| US-20230110122-A1 | COMPOUNDS AND THEIR USE | NLRP3, PYCARD, NLRP1 | ENPP2 1431/4885ORAI1 741/4885ORAI2 1534/4885 |
| US-12410187-B2 | Fused tricyclic compounds useful as anticancer agents | MCL1, TP53, CCNA2 | ENPP2 3123/4885ORAI1 4618/4885ORAI2 4767/4885 |
| US-20130079345-A1 | PHARMACEUTICALLY ACTIVE DISUBSTITUTED TRIAZINE DERIVATIVES | PDE5A, TESK2, PAK5 | ENPP2 815/4885ORAI1 2267/4885ORAI2 2496/4885 |
| US-10927125-B2 | Substituted cinnolines as inhibitors of KRAS G12C | KRAS, NRAS, HRAS | ENPP2 3390/4885ORAI1 2488/4885ORAI2 4325/4885 |
| US-20190343838-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | ENPP2 698/4885ORAI1 4675/4885ORAI2 3377/4885 |
| US-20170107205-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | ENPP2 468/4885ORAI1 1787/4885ORAI2 735/4885 |
| US-20250325552-A1 | SUBSTITUTED THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | POLQ, POLK, POLH | ENPP2 3208/4885ORAI1 4844/4885ORAI2 4777/4885 |
| US-20080182891-A1 | CHROMANE AND CHROMENE DERIVATIVES AND USES THEREOF | HTR1A, HTR2C, CHRM1 | ENPP2 1677/4885ORAI1 2158/4885ORAI2 2280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.